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Abstract 
Drosophila melanogaster, a key model organism, has cognates of over 70% of 
human disease genes. This has created opportunities in the development of 
treatments for life threatening illnesses like cancer. Mutations on the p53 
tumour suppressor protein, which is an activator of apoptosis, are common 
in many cancers. In mammals, p53 interacts with the Retinoblastoma Binding 
Protein 6 (RBBP6) which enhances the activity of MDM2, the prototypical 
negative regulator of p53, that is absent in invertebrates. In the absence of 
MDM2 the Drosophila RBBP6 homolog, SNAMA, through its DWNN Catalytic 
Module (DCM), is suspected to play an important role in the regulation of 
p53, probably via the ubiquitin proteasome pathway. Through bioinformatics 
analyses, and experimental analysis of transcripts, this study has shown the 
existence of two isoforms of SNAMA named here SNAMA A and SNAMA B for 
the long and short isoforms, respectively. SNAMA B appears to be expressed 
after genotoxic stress (DNA damage) in adults as well as during embryonic 
development. Recombinant protein expression in bacterial and yeast systems 
as well as HIS-tag chromatography and Western blot analyses were used to 
investigate interactions with Dmp53. Due to poor expression of recombinant 
Dmp53 protein in both prokaryotic and eukaryotic systems and unreliable 
commercial antibodies, it was impossible to complete interaction studies. 
Overall, these studies show that the SNAMA isoforms may play important 
roles during development and in response to DNA damage. 
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Quotation 
“Alice: You're quite right, Mr. Hatter. I do live in a topsy-turvy world.  
 It seems like I have to do something wrong first, in order to learn from 
what not to do. And then, by not doing what I'm not supposed to do, 
perhaps I'll be right. But I'd rather be right the first time,  
wouldn't you?” 
Lewis Caroll –Alice in Wonderland 
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1. Introduction 
Cancer is a disease that refers to an accumulation of cells or a certain 
degree of uncontrolled growth of cells, which have transformed from 
normal to an abnormal or diseased state. This collection of cells or 
tumour may remain localised or spread to other parts of the body in a 
process known as metastasis (Hanahan and Weinberg, 2000; Vidal and 
Cagan, 2006). To date cancer remains one of the leading causes of 
death worldwide. In a study conducted on cancer records from 2008, 
by (Ferlay et al., 2010), it was found that the most common cancers 
were lung, breast and colorectal cancers, while lung, stomach and liver 
cancers accounted for most deaths. Furthermore, over half of cancer 
cases and deaths occurred in less developed regions in Africa, Central 
and South America and Asia (Ferlay et al., 2010). Causes of cancer are 
varied, and include heredity and lifestyle stresses.  
Over a hundred different human cancer types exist (Selivanova, 2004). 
These complex and diverse diseases are a result of what appears to be 
an endless number of combinations of genetic and epigenetic changes 
(Selivanova, 2004; Vidal and Cagan, 2006). It would seem that these 
diverse diseases would therefore require different types of therapies. 
However, recent advances in understanding the molecular biology of 
tumours has enabled the design of therapies directed against a variety 
of tumours that target a finite number of specific pathways, amongst 
these the p53 pathway in particular (Selivanova, 2004). Amongst genes 
involved in tumour development, the tumour suppressor protein p53 
stands out. The inactivation of p53 function, occurs in virtually all 
human tumour varieties. Mutations in the p53 gene, causing 
inactivation of p53 protein (an important DNA damage detector which 
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activates apoptosis) is common in more than half of human cancers 
(Farnebo et al., 2010; Hanahan and Weinberg, 2000). p53 is also found 
in a number of lower eukaryotes, including Drosophila in which cancer 
is not naturally prevalent (Dichtel-Danjoy et al., 2012) 
 
1.1 Drosophila as a model organism 
Model organisms have become a key in the study of human disease, 
where treatments and causes can be researched feasibly and ethically. 
Organisms, such as the common fruit fly – Drosophila melanogaster, are 
extensively studied due to advantages they provide (Daines et al., 
2010). Conservation of genetic material as well as pathways, both 
metabolic and developmental, allow for the elucidation of biological 
workings in other organisms. Drosophila has been adopted as a key 
model organism because of its complete genomic sequence being 
available, as well as the similarity that exists between it and other 
systems. Ease of breeding, small size, low cost of maintenance and the 
ability to manipulate the fly are other factors making Drosophila more 
amenable for experimentation. In 2001, Reiter et al., found that 77 
percent of human disease genes have cognates in Drosophila. This 
includes the tumour suppressor p53. Drosophila melanogaster p53 
(Dmp53) shares similar functions with multiple mammalian p53 family 
members. This makes Dmp53 an attractive model system to study 
apoptotic pathways involving p53 activation (Fan et al., 2010; Herzog et 
al., 2012).  
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1.2 History and Role of p53 and Dmp53 
The p53 protein, discovered in 1979, is a well-known tumour 
suppressor gene product (Farnebo et al., 2010; Machado-Silva et al., 
2010). To date p53 studies have been somewhat limited to 
mammalian systems and thus more is known about the human 
homologue than that of the fly. On activation, p53 induces apoptosis, 
the repair of DNA, or cell cycle arrest, by different mechanisms 
(Schuler and Green, 2005). The inactivation of the p53 gene serves as 
a marker for cancer as it is the most common event in human 
cancers (Bourdon, 2005; Farnebo et al., 2010). Furthermore, p53 is 
mutated in 50 percent of all cancers and mutations in the gene 
increase the risk of cancer development (Bourdon, 2005; Murray-
Zmijewski et al., 2006). 
 
There is significant similarity between human p53 and its 
paralogues (p63 and p73). These paralogues can sometimes mimic 
the action of p53 by binding p53 targets or inducing cell cycle arrest 
and apoptosis (Bourdon, 2005; Khoury and Bourdon, 2009). 
Drosophila p53, however, has no paralogues. Instead three 
theoretical isoforms identified by Bourdon and colleagues (2005) 
exist, as confirmed by a recent review of the Dmp53 gene structure, 
through its 2 internal promoters (Marcel et al., 2011). These 
isoforms are described as the Dmp53 long isoform of 495 amino acid 
sequence, the originally published Dmp53 of 385 amino acid length 
and lastly Dmp53n (110 amino acids). It was shown that the 
originally discovered Dmp53 was a truncated form of the long 
isoform generated by transcription initiated at an internal promoter 
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region (Bourdon, 2005). The three isoforms are diagrammatically 
represented in Figure 1. 
 
Figure 1: Schema of Drosophila p53 isoforms. The figure shows the 
3 domains of p53 and the 3 isoforms formed by variation in these. 
Dmp53L is the long isoform, and Dmp53 was the originally published 
isoform. Dmp53n is the shortest isoform, but only contains the 
transactivation domain (adapted from Bourdon, 2005). 
 
The schema identifies 3 major regions in Dmp53. The transactivation 
domain and oligomerisation domain are responsible for binding 
regulatory proteins and post translational modifications. These 
domains flank a central DNA binding core domain (Dichtel-Danjoy et 
al., 2012). Furthermore, on comparison to other p53 family members 
this core domain is conserved and shows a high degree of similarity to 
the DNA binding domains from p53 proteins from other species. The 
core domain functions to recognise and bind DNA as well as co-
ordinate a zinc ion, through the presence of vital amino acid residues 
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(Brody, 2000). The similarity of the core region extends to the three 
dimensional structure of the protein, which suggests similarity in 
function. Aligned 3D structures of p53 and Dmp53 are shown in  
Figure 2.  
 
 
Figure 2: Superimposed crystal structures of human and 
Drosophila p53. Human p53 is shown in yellow and Dmp53 in red, the 
structures were predicted by Jin et al., (2000) using ‘MODELLER’. 
 
p53 is toxic in high quantities and may cause the death of the organism 
if not regulated. Kim et al., (2011), explain that p53 regulation involves 
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protein stabilisation, interactions, modification, and localization; 
furthermore, this stabilisation is important in its activation. As such, 
p53 in humans normally exists in a latent form and in low quantities 
(Brooks and Gu, 2006). This stringent regulation is largely a result of 
the ubiquitin proteasome pathway, and the E3 ligase Mouse Double 
Minute 2 (MDM2). While p53 inactivation in cancers is often through 
direct mutation of the p53 gene, its function is also sometimes affected 
through an increased level of MDM2, a downregulator of p53 (Michael 
and Oren, 2002). MDM2 binds the transactivation domain of human 
p53 and regulates p53 transport to the cytoplasm and its degradation 
by ubiquitination. This occurs in the absence of external factors 
(Brooks and Gu, 2006; Jin et al., 2000).  
 
An MDM2 homologue is yet to be discovered in Drosophila 
melanogaster. As such, the regulation of p53 in invertebrates is not 
clearly understood, and its pathways are not completely known. In 
Drosophila, Dmp53 is required for apoptosis. Peculiarly, Dmp53 does 
not block the cell cycle at the G1 phase (Ollmann et al., 2000). Ollmann 
et al., (2000), explain that this reveals an ancestral proapoptotic 
function for Dmp53, induced by DNA damage. This makes Drosophila a 
model system to study and elucidate programmed cell death pathways. 
   
1.3  Apoptosis 
When the p53 tumour suppressor is activated, it induces apoptosis. 
Apoptosis, or programmed cell death (PCD), is a highly regulated 
biological process in multicellular organisms. The mechanism is 
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present throughout the organism’s development from embryo to adult, 
cell homeostasis, and the body’s defense mechanisms. During 
apoptosis, cells commit suicide in an orderly fashion when signaled to 
do so. Apoptosis generally occurs when cells are under stress; infected 
by viruses, damaged beyond repair, or have undergone DNA damage. In 
contrast, necrosis, or uncontrolled cell death, results in cell lysis, 
immune responses and other unfavourable conditions. An underlying 
characteristic of cancer is an impaired apoptotic mechanism; damaged 
cells, which have impaired or irregular function, continue dividing and 
tumours often develop. According to Hanahan and Weinberg (2000), 
the rate of tumour progression is dependent not only on cell 
proliferation rate but also that of cell attrition, which is predominantly 
as a result of PCD. 
 
1.4  Apoptosis in Humans 
Comparison of the apoptotic pathways of humans, Drosophila and the 
nematode C. elegans (another model organism) reveals that the fly 
provides a system with intermediate complexity. The fly system, as 
described by Richardson and Kumar (2002), has less redundancy 
thereby allowing simpler analysis of function than these systems. Two 
main activation routes divide the human apoptotic pathway into two 
component pathways; namely the intrinsic and extrinsic pathway. 
Although activated by different triggers, both pathways activate a 
common signal transduction cascade (STC) of cysteine proteases, 
otherwise known as caspases, which results in cell death.  
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The human extrinsic pathway is activated primarily by ligand-
stimulated activation of receptors, such as FAS ligand binding to the FAS 
receptor, thus activating the STC. The intrinsic pathway is associated 
with a buildup of both death promoting and death inhibiting molecules 
on the mitochondrial outer membrane. Cell death ensues when the 
presence of death promoters, such as Bax, outweighs the presence of 
death inhibitors, such as Bcl-2. This causes the release of cytochrome C 
from the mitochondria, which in turn binds Apaf-1, activates the STC 
(Richardson and Kumar, 2002).  
 
1.5 Apoptosis in Drosophila 
The Drosophila apoptotic mechanism is remarkably similar to the 
mammalian mechanism. Many of the proteins involved in the human 
apoptotic pathway have homologues, which are present in that of the 
fly. It is therefore thought that the apoptotic mechanism in Drosophila 
has in essence been maintained through evolution and is a conserved 
form of the pathway. The human pathway's classical tumour necrosis 
factor receptor (TNFR) family of death receptors which signal apoptosis 
in the extrinsic mammalian pathway, are represented in the fly by Eiger 
and Wengen (Kauppila et al., 2003). Eiger and Wengen share a Fadd 
homologue, dFadd, and caspase 8 homologue, Dredd (Richardson and 
Kumar, 2002). In mammals, cytotoxic agents and stress activate the 
intrinsic pathway by the activation of p53. Dmp53, induces expression 
of pro-apoptotic, Reaper (Rpr) (Brodsky et al., 2000). The PCD inducers 
in Drosophila are Rpr, Grim and Hid, with Smac/Diablo being possible 
functional homologues in mammals. These inducers, may act upon 
DARK (APAF-1 in mammals) directly, or cause the release of 
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cytochrome C from the mitochondrion, which acts upon DARK via Debcl 
(Bcl2 in mammals). DARK initiates the Drosophila STC via the initiator 
caspases. An overview of the apoptotic pathway in humans is shown in 
Figure 3. Figure 4 compares the apoptotic mechanisms of humans and 
Drosophila.  
 
Figure 3: A diagrammatic overview of the Apoptotic mechanism in 
humans. Initiation of apoptosis may be via an extrinsic pathway, where 
an external ligand binds its receptor and activates a signal transduction 
cascade of caspases, or via an intrinsic pathway where cytotoxic 
molecules or stresses cause cytochrome c release from the 
mitochondria, which activates the same cascade through Apaf-1 
(Genentech, 2014). 
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Figure 4: A comparison between the apoptotic mechanisms of 
Drosophila, and humans. The Drosophila mechanism is shown in 
black and that of humans is shown in red. Question marks are shown 
where uncharacterised steps occur (adapted from Richardson and 
Kumar, 2002).  
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1.6  Ubiquitin and Ubiquitination 
The ubiquitin-proteasome pathway plays a major role in p53 
regulation through MDM2. The ubiquitin pathway as described 
previously by Hershko and Ciechanover (1998), begins with the 
activation of ubiquitin, by the E1 enzyme Ubiquitin Activating Enzyme. 
The reaction requires ATP and conjugates ubiquitin at its Gly-76 to a 
Cys residue on the enzyme. The second step in the pathway involves 
the transfer of ubiquitin to an E2 enzyme, Ubiquitin Conjugating 
Enzyme. The ubiquitin once again is specifically transferred to a Cys 
sulphydryl group on the enzyme. The final step in the pathway is the 
transfer of the activated ubiquitin from the E2 enzyme to a Lys ε amino 
group on the target protein. This is carried out by an E3 enzyme, 
ubiquitin-protein ligase. Each E3 is specific to a specific set of proteins. 
The poly-ubiquitinated protein, depending on the length of the 
ubiquitin side-chain, undergoes a specific fate. Generally, targeted 
proteins with 4 or more linked ubiquitin molecules are degraded by 
hydrolysis in the Proteasome. Figure 5 gives an overview of the 
ubiquitin proteasome pathway and the fates of target protein 
depending on where and how many ubiquitin molecules are linked.  
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Figure 5: The ubiquitin pathway of RING class E3 ligases which 
interact directly with E2 and the fates of proteins ubiquitinated by 
the pathway, as described by Ohta and Fukuda (2004). 
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The E3 ligases are the most important in the pathway. They bind a 
target protein specifically and are divided into 3 classes. Of the three 
classes, the largest class is that of the RING (Really Interesting New 
Gene) family. MDM2, a negative regulator of p53 mentioned previously, 
is perhaps the most well-known E3 enzyme in the p53 apoptotic 
pathway. MDM2 is not present in invertebrates but other 
commonalities between systems have been identified, for example 
RBBP6.  
1.7 RBBP6 and SNAMA 
Retinoblastoma binding protein 6 (RBBP6) is a homo sapiens E3 ligase, 
characterised by the presence of a RING finger domain (Mather et al., 
2005; Pugh et al., 2006). This nuclear protein is also one of the few 
known regulators of p53. The RBBP6 human homolog has 
Retinoblastoma protein (Rb) and p53 protein binding sites at its  
C terminal end, implicating it in regulating the cell cycle and apoptosis 
(Mbita et al., 2011; Simons et al., 1997). It has been identified as a 
down-regulator of p53, which functions by blocking the binding of p53 
to DNA (Pugh et al., 2006). RBBP6 homologs all share a N terminal 
region, called the DWNN (Domain With No Name) catalytic module 
(Antunes, 2008). This module contains a DWNN domain, a Zinc knuckle 
and RING finger. DWNN has approximately 28% identity with 
ubiquitin, but has an almost exactly matching 3 dimensional structure 
to it (Cajee et al., 2012). The homologue of this protein in Drosophila is 
the recently characterised SNAMA (Mather et al., 2005). SNAMA, like 
RBBP6, is an E3 ligase and catalyses the addition of ubiquitin side 
chains to a substrate due to the presence of the DCM (Antunes, 2008). 
Research to date has shown that only SNAMA’s homologs in mice (P2P-
R) and humans (RBBP6) are known to bind p53 and Retinoblastoma 
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protein (Rb) (Simons et al., 1997). SNAMA has recently been shown to 
exhibit E3 ligase activity (Antunes, 2008) and contains a long 
uncharacterised C terminal extension (Mather et al., 2005) which may 
have a p53 binding site. We therefore suspect that it plays a role in 
transcriptional regulation and cell cycle control as suggested by Mather 
et al., in a 2005 study. 
1.8 Overview, Aim and Objectives 
Little is known about the regulation of p53 in invertebrates. When 
activated, p53 induces apoptosis, the repair of DNA, or cell cycle arrest, 
by different mechanisms. The inactivation the p53 gene, is the most 
common event in human cancer and these mutations increase the risk 
of cancer development. p53 has a high degree of toxicity in high 
quantities, and must therefore be regulated in order to prevent the 
death of the organism.  
Recent studies have found that Drosophila have a third p53 isoform 
which has not yet been characterised completely. In addition, its 
interactions and regulation is yet to be determined (Dichtel-Danjoy et 
al., 2012).  
By studying this protein in this model organism, we can draw 
comparison to the human system and thereby increase our knowledge 
of the human homologues of these molecules. New knowledge of p53 
regulation and interactions will lead to new drugs being developed, and 
the identification of other key role players.  
In an attempt to gain more insight into the regulation of p53 in 
Drosophila, we ask what other regulatory proteins exist, and 
specifically do SNAMA and Dmp53 interact? Furthermore, what is the 
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role of SNAMA in Drosophila p53 regulation? We attempt to answer this 
by determining whether p53 can act as a substrate for SNAMA. 
The first stage of this research involved the isolation of the Drosophila 
p53 protein. This protein was to be expressed in vitro and used in 
various studies to determine what other proteins interact with it, as 
well as any specific interactions with the SNAMA protein and ubiquitin. 
By identifying role players in p53 pathways, one can attempt to 
regulate these role players and thereby regulate downstream processes 
such as cell death and the cell cycle.  
The main aim of this study was to express and purify Drosophila p53, 
which would be used in protein interaction studies to determine 
whether SNAMA or any other proteins are involved in Dmp53 
regulation.  
The main aim was to be achieved by reaching the following objectives: 
1. To heterologously express the long isoform of Drosophila p53 in  
E. coli, for solubility studies.  
2. To purify the p53 protein expressed by the E. coli.  
3. To heterologously express the long isoform of Drosophila p53 in 
Saccharomyces cerevisiae (Tgy 48-1).  
4. To purify the p53 expressed by the S. cerevisiae Yeast (Tgy 48-1).  
5. To perform immunoprecipitation studies using purified Dmp53, 
and anti Dmp53 purified antibodies.  
 
Furthermore, an attempt was made to gain further insight into both the 
Dmp53 and SNAMA genes through bioinformatic analyses.   
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2. Materials and methods 
 
2.1 Materials 
 
2.1.1 Flies 
Drosophila melanogaster Oregon R, adult flies and fly embryos were 
utilised where required throughout the study. Flies are bred in the 
laboratory, under 12hr day night cycles at a constant 25°C.  
 
2.1.2 Bacterial Cells 
Table 1: Bacterial Cell Strains used 
 Supplier #catalogue no. 
Epicurian Coli BL21 (DE3) pLysS 
Competent Cells 
Stratagene #200132 
 
E. cloni 10G Chemically Competent 
Cells DUOs 
Lucigen #60107 
 
One shot Top10 Chemically 
Competent E. coli 
Invitrogen # C4040-10 
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2.1.3 Bacterial plasmids 
Table 2: Bacterial Plasmid DNA used  
 Supplier #catalogue no. 
Pet-41a (+) (Appendix C) Novagen #70556-3  
pGEM-T Easy Vector System 1 (Appendix B) Promega  #A1360 
 
2.1.4 Yeast 
Saccharomyces cerevisiae (strain Tgy 48-1) as well as yeast expression 
plasmid pTG1895 (Appendix D) were kindly provided by Jean Marc 
Reichhart, University of Strasbourg, France. 
 
2.1.5 Media 
Table 3: Composition of media for flies, bacteria and yeast 
maintenance  
 Recipe 
Apple Juice agar 1.25% sucrose2% agar 
0.025% streptomycin 
0.25% methyl paraben 
25% (v/v) Apple juice 
Cornmeal Molasses agar 1% sucrose 
0.75% agar 
5% molasses 
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7.5% cornmeal 
2.5% yeast 
0.05% methyl paraben 
Luria-Bertani Broth (LB) 1% Tryptone 
0.5% Yeast extract 
1% NaCl 
LB Agar LB+ 1.5% Agar 
YPG 2% Peptone 
1% Yeast extract  
(pH5.8) 
0.004% adenine sulphate 
2%Glucose 
YPG agar YPG + 1.5% Agar 
Synthetic Minimal (SD) 
media 
0.67% Yeast Nitrogen Base 
18.22% D-Sorbitol 
(pH 5.8) 
10% 10x Dropout Solution 
2% Glucose 
SD agar SD + 1.5% Agar 
10 x Dropout Solution 300mg/l     L-Isoleucine 
1500mg/l   L-Valine 
200mg/l     L-Adenine Hemisulfate salt 
200mg/l     L-Arginine HCl 
200mg/l     L-Hisitidine HCl monohydrate 
300mg/l     L-Lysine HCl 
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200mg/l     L-Methionine 
500mg/l     L-Phenylalanine 
2000mg/l   L-Threonine 
200mg/l     L-Tryptophan 
300mg/l     L-Tyrosine 
1000mg/l   L-Glutamic acid 
1000mg/l   L-Aspartic acid 
4000mg/l   L-Serine 
 
2.1.6 Selection/antibiotic resistance 
Table 4: Antibiotic resistance and selection of bacterial and yeast, 
cells and plasmids. 
  Concentration in 
media 
Epicurian Coli BL21 
(DE3) pLysS  
Chloramphenicol 
(Cm)  
100µg/ml (stock 
34mg/ml in 
ethanol) 
E. cloni 10G DUOs  Streptomycin (Sm)  50µg/ml  
One shot Top10  Ampicillin (Amp)  50 µg/ml 
Pet41a Kanamycin (Kan)  30 µg/ml 
pGEM-T Easy Ampicillin (Amp)  50 µg/ml 
Yeast Tgy 48-1/pTG1895 Ampicillin (Amp) & 
SD -leucine –uracil 
50 µg/ml 
20 
 
2.1.7 Buffers and other solutions 
Table 5: Composition of Solutions and buffers used in the study 
Birnboim 1 (resuspension buffer) 50mM Tris.HCl pH8.0 
10mM EDTA 
100μg/ml RNAse A 
Birnboim 2 (Lysis Buffer) 200mM NaOH 
1% w/v SDS 
Birnboim 3 (Neutralization 
Buffer) 
3M Potassium Acetate pH5.5 
Ethanol Acetate 24 Parts Absolute Ethanol 
1 part Sodium Acetate pH5.2 
Bacterial Lysis Buffer  
 
50mM Tris-HCl pH7.5 
2mM EDTA 
200mM NaCl 
2mM DTT 
0.1% Triton-X 100 
0.1% PMSF 
200 μg/ml Lysozyme 
3mM MgCl2 
 
21 
 
Bacterial Denaturation Buffer 8M Urea 
50mM Sodium Phosphate 
buffer pH 7.5 
0.1 M NaCl 
1mM PMSF 
2mM DTT 
Yeast Lysis Buffer 50mM Tris HCl pH8 
1% DMSO 
200mM NaCl 
1mM EDTA 
1mM PMSF 
1 μg/ml Leupeptin 
Transfection Mix  
(per Transfection) 
240μl PEG3500 w/v 
18 μl Lithium Acetate 2.0M 
47μl H2O 
Genomic DNA grinding buffer 
 
5% Sucrose 
80mM MgCl2 
100mM Tris pH 8.5 
0.5% SDS 
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50mM EDTA 
Southern blotting: nucleic acid 
transfer buffer (20x SSC) 
 
8.823% TriSodium Citrate 
17.532% NaCl 
pH 7-8 
Southern blotting: Depurination 
buffer 
 
11ml HCl  
989ml dDH2O 
Southern blotting: Denaturation 
buffer 
8.766% NaCl 
2% (w/v) NaOH 
Southern blotting: Neutralization 
buffer 
8.766% NaCl 
6.05% Tris 
pH 7.5 
Southern blotting: Hybridization 
Solution 
 
5X SSC 
1% Blocking Solution 
0.1% N Lauryl Sarcosine 
0.02% SDS 
1.5 % Roche DIG Easy Hyb 
Southern blotting: Low stringency 
wash buffers 
2X SSC 
0.1% SDS 
Southern blotting: Medium 
stringency wash buffers 
1X SSC 
0.1% SDS 
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Southern blotting: High stringency 
wash buffers 
0.1% SSC 
0.1% SDS 
Camptothecin stock 50 mM In DMSO 
Coomassie stain 
 
0.1% Coomassie Blue R-250 
40% ethanol 
10% glacial acetic acid 
50% ddH20 
Coomassie destain 
 
40% ethanol 
10% glacial acetic acid 
50% ddH20 
SDS PAGE running buffer 5x 
 
25mM Tris Base 
192mM Glycine 
0.1% SDS 
Distilled water to 3L 
pH8.3 
SDS PAGE sample buffer 
 
62.5mM Tris-HCl pH6.8 
10% Glycerol 
2% SDS 
5% B-Mercaptoethanol 
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0.05% Bromophenol Blue 
50% ddH20 
Towbin 
 
25mM Tris Base 
192mM Glycine 
0.1% SDS 
20% Methanol 
pH8.3 
PBS 10x 1.4M NaCl 
27mM KCl 
0.1M Na2HPO4 
18mM KH2PO4 
pH to 7.4 with HCl 
PbsT 
 
1X PBS + 0.1% Tween 20 
HIS nickel chromatography native 
conditions equilibration buffer 
 
50mM Sodium Phosphate pH8.0 
0.3M NaCl 
10mM Imidazole 
HIS nickel chromatography native 
conditions wash buffer 
50mM Sodium Phosphate pH8.0 
0.3M NaCl 
10mM Imidazole 
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HIS nickel chromatography native 
conditions elution buffer 
50mM Sodium Phosphate pH8.0 
0.3M NaCl 
250mM Imidazole 
HIS nickel chromatography 
denaturing conditions 
equilibration buffer 
0.1M Sodium Phosphate pH 8.0 
8M Urea 
HIS nickel chromatography 
denaturing conditions wash buffer 
0.1M Sodium Phosphate pH 6.3 
8M Urea 
HIS nickel chromatography 
denaturing conditions elution 
buffer 
0.1M Sodium Phosphate pH 4.5-
6.0 
8M Urea 
2.1.8 Primers for PCR 
Table 6: Primer sequences used in Polymerase Chain reaction  
Dmp53 
p53 for: 5ˊ AGGAGATATACAAGCTTCCCCTATAC 3ˊ 
Sal1p53rev: 5ˊ GTCGACTTCATGGCAGCTCGT  3ˊ 
pET41histag: 5ˊ TAGTGAAGCTTGTCATCACCAT            3ˊ 
Biotin probe 
p53.biotin.fwd:  5ˊ  ATGTACTCGATTCCGCTGAACAAGC  3ˊ 
SNAMA A&B 
ABfwdexon3SNAMA 5ˊ TGAGGAATTCGGTGAACG              3ˊ 
BrevUTRSNAMA  5ˊ ATCCACATGGTAGCGGGAT  3ˊ 
ArevEXON7SNAMA 5ˊ CAACGGATCGTCAATGG    3ˊ 
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2.1.9 Antibodies 
Table 7: Primary Antibodies used in Western blot analysis 
  Antibody 
target 
Supplier 
#catalogue no. 
Anti-Drosophila 
p53 (dD-21) 
goat 
polyclonal 
IgG 
internal 
epitope  
Santa Cruz #sc-
17577 
Anti-Drosophila 
p53 (dA-17) 
goat 
polyclonal 
IgG 
C-terminal Santa Cruz #sc-
17578 
Anti-Drosophila 
p53  
(d-200) 
rabbit 
polyclonal 
IgG 
186-385 Santa Cruz #sc-
25767 
 
Table 8: Secondary Antibodies used in Western blot analysis 
 Supplier #catalogue no. 
Anti-Goat IgG (whole molecule)–
Peroxidase antibody produced in 
rabbit  
Sigma Aldrich #A8919 
Anti-Rabbit IgG (whole molecule)–
Peroxidase antibody produced in 
goat 
Sigma Aldrich #A0545 
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2.1.10 Restriction Enzymes 
Table 9: Restriction enzymes used for DNA digestion 
 Supplier #catalogue no. 
HindIII NEB: #R0104 
Roche: #10656321001 
Fermentas: #ER0505 
SalI NEB: #R0138 
Roche: #10567663001 
Fermentas: #ER0645 
BamHI NEB: #R0136 
Roche: #10656275001 
Fermentas: #ER0055 
EcoRI NEB: #R0101 
Roche: #11175084001 
Fermentas: #ER0275 
XhoI NEB: #R0146 
Roche: #10899194001 
Fermentas: #ER0695 
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2.1.11 Molecular weight Markers 
Table 10: Molecular Weight markers used in DNA and Protein 
Electrophoresis 
  Supplier #catalogue no. 
DNA  Gene ruler 1kb plus Fermentas #SM1331 
Protein  Pageruler Prestained 
Protein ladder 
Fermentas #SM0671 
 
2.1.12 General reagents and kits 
Table 11: General reagents and kits used 
 Supplier #catalogue no. 
FastAP Thermosensitive Alkaline 
Phosphatase 
Fermentas #EF0651 
t4 DNA ligase Fermentas #EL0015 
HIS select nickel affinity gel Sigma #p6611 
Super block Pierce Thermo Scientific #37545B 
Chemiluminescent Nucleic Acid 
Detection Module kit 
Pierce Thermo Scientific #89880 
glass beads unwashed 425-600um Sigma Aldrich #g9268 
unitek glass beads 5mm Merck Millipore #104017 
DNA clean & concentrator-5  kit   Zymo Research #d4003 
Nuclease free water Qiagen #129115 
SuperSignal® West Pico 
chemiluminescent substrate 
Pierce Thermo Scientific #34080 
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TRI reagent (TRIzol) Sigma Aldrich #T9424 
RevertAid Reverse Transcriptase  Fermentas #EP0441 
RevertAid First Strand cDNA 
synthesis kit 
Fermentas #K1622 
PCR Master Mix Fermentas #K0171 
DIG Easy Hyb Roche #11603558001 
Taq DNA Polymerase with 
Standard Buffer 
NEB: #M0273S 
Fermentas: #EP0402 
10mM dNTP mix Fermentas: #R0192 
Oligo(dT)18 Primer (0.5µg/µl) Fermentas #S0131 
25mM MgCl2 Thermo Scientific #R0971 
IPTG Sigma Aldrich #i5502 
PALL Biotrace PVDF  #66543  
Kodak Biomax film  #8194540), 
Axim fixer    #ffc-fixruhs10bb 
Axim developer #fdc-devru0010bb 
 
2.1.13 Initial clone 
A clone of E. coli BL21 (DE3) pLysS transformed with an N terminal 
truncated Dmp53 insert in pET41a plasmid was kindly provided by 
Brent Oosthuysen. The sequence of this insert appears in Appendix A.  
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2.2 Methods 
2.2.1 Bioinformatics 
A sequence analysis of the gene, mRNA and protein sequences of p53 
and SNAMA was undertaken using online tools and databases (flybase, 
NCBI, Clustal W2) and the DNAman (Lynnon Biosoft v4.03) software 
package.  
 
2.2.2 Agarose gel electrophoresis 
Following PCR or restriction digestion, DNA was analysed using 
agarose gel electrophoresis. DNA was separated on a 1% Agarose gel 
with Fermentas Generuler 1kb plus (Appendix E) as a molecular weight 
marker. Ethidium bromide (EtBr) was used as a visualising agent and 
Gels were visualised on a calibrated Bio-Rad Gel Doc XR. For DNA 
purification from gels, EtBr was replaced with sybr gold and visualised 
on a Dark reader system from Clare.  
 
2.2.3 Gel purification of DNA 
For ligation into plasmids, DNA inserts of interest were excised from a 
1% agarose gel, and purified using the Zymo DNA Clean and 
Concentrator kit, as per manufacturer’s instructions. DNA was 
resuspended in nuclease free water. 
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2.2.4 Plasmid DNA purification by ethanol acetate method 
Preparation of plasmid DNA, pTG1895 and pET41a containing Dmp53 
insert, was performed based on the method of Birnboim (1983). The 
cells were lysed and DNA, proteins and cell debris was pelleted by 
centrifugation. Thereafter pellets were resuspended and DNA 
separated out into the supernatant fraction. The DNA was precipitated 
by ethanol acetate precipitation. Isopropanol was used to further 
precipitate DNA. Contaminating salts were removed from the DNA 
pellet by washing with 70% ethanol. The pellet was air-dried and the 
DNA was resuspended in nuclease free water. 
 
2.2.5 Restriction digestion of DNA 
Restriction digestion of DNA was performed according to 
manufacturer’s instructions. Digestions were incubated overnight at 
37oC.  
a. p53 and pTG1895 were hydrolysed with HindIII and SalI for 
cloning 
b. p53 in pET41a was hydrolysed with HindIII and BamHI for 
linearization.  
c. Cloned pGem-T Easy plasmid DNA was hydrolysed with EcoRI to 
screen for p53 insert. 
d. Genomic DNA was hydrolysed with EcoRI, SalI and BamHI, SalI 
and XhoI, for Southern blotting. 
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2.2.6 Preparation of plasmid DNA for ligation 
(dephosphorylation) 
Following restriction enzyme digestion of pTG1895 Plasmid DNA, the 
resulting linear DNA was subsequently dephosphorylated using 
alkaline phosphatase (Fermentas #EF0651) according to the 
manufacturer’s instructions. 
 
2.2.7 Ligation of insert into linearised plasmid 
p53 fragment (from the initial clone supplied by Brent Oosthuysen) 
was cloned into  pTG1895 as well as into pGEM-T Easy vector using T4 
DNA ligase (Fermentas #EL0015), according to manufacturer’s 
instructions.  
 
2.2.8 Transformation of chemically competent cells  
The following transformations of chemically competent cells were 
performed. 
 E. cloni Duos cells were transformed with intact pTG1895. 
For large-scale preparation of pTG1895 plasmid, the 
recombinant plasmid was used to transform E. cloni Duos cells 
(Lucigen #60107) as per manufacturer’s instructions. 1µl cells 
were heat shocked at 42°C for 45 seconds and cold snapped on 
ice for 2 mins. Clones were screened for insert using 
Ampicillin/Streptomycin resistance.  
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 E.cloni Duos cells were transformed with p53 in pGEM-T Easy. 
For gel purification of p53 insert, p53 was amplified by PCR from 
the initial clone, and transformed into pGEM-T Easy vector. This 
ligation reaction was used to transform E.cloni duos cells 
(Lucigen #60107) as per manufacturer’s instructions. Clones 
were screened for insert using Blue/White screening and 
Ampicillin/Streptomycin resistance. 
 
 Top10 cells were transformed with p53 in pTG1895.  
p53 was ligated into pTG1895 plasmid and the ligation reaction 
was used to transform top10 competent cells (Invitrogen 
#C4040-10) as per manufacturer’s instructions. Clones were 
screened for insert using Ampicillin resistance. 
 
Resulting colonies were screened through restriction digest analysis. 
Clones that contained the recombinant plasmid were used to inoculate 
large-scale cultures. Recombinant plasmid DNA was then isolated from 
these cultures.  
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2.2.9 Transfection of yeast  
From a 2ml overnight preculture of untransfected yeast, a 100ml 
culture was inoculated and grown at 30°C to an OD of 0.5. The yeast 
cells were pelleted, the supernatant was discarded and the pellet 
resuspended in the residual fluid. This was transferred to a smaller 
microcentrifuge tube and the cells were pelleted, the supernatant was 
discarded and the cells were washed in water (H2O). The cells were 
pelleted again and then resuspended in water to a ratio of 10ml of 
0.5ml culture: 50µl water. Each of these aliquots was then transfected. 
For transfection, 100µg of salmon sperm DNA was added to 50µl of 
yeast cells from above, and mixed by pipetting. To this 10µl of plasmid 
DNA (p53 in pTG1895) was added. 305µl of transfection mix (Lithium 
Acetate, PEG3500) was added, and the tube mixed by vortexing, before 
incubation at 42°C for 40mins. After incubation cells were pelleted at 
3000g for 1min, the supernatant was discarded and the cells washed 
with water. A further round of washing was performed before the cells 
were resuspended in 100µl water and plated on synthetic minimal 
medium containing Ampicillin and standard dropout solution without 
Leucine and Uracil. Plates were incubated at 30°C. 
 
2.2.10 Protein expression 
Protein expression in bacteria was performed in cultures containing 
Chloramphenicol (100µg/ml) and Kanamycin (30µg/ml) (inoculated 
from a starter culture of the initial clone). The cultures were grown to 
an OD600 of 0.6, upon which expression was triggered using IPTG added 
to a final concentration of 0.2mM. Cultures were incubated on a 
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shaking platform incubator at 37°C, for a specified time (0, 2, 4, 6 
hours). Following this, cells were spun down at 6000g for 15 mins at 4-
10°C. All supernatants were retained for analysis. 
 
For small culture expressions 2ml cultures were used. The cultures 
were grown to an OD600 of 0.6, upon which expression was triggered by 
adding IPTG to a concentration of 0.1mM. Cultures were incubated on a 
rotating mixer, in a walk in 37°C incubator room. 0, 2, 4 and 6 hour 
expressions (after induction) were pelleted by centrifugation at 6000g 
for 5 mins. All supernatants were retained for analysis.  
 
2.2.11 Protein extraction 
Pelleted bacterial cells were resuspended in lysis buffer (20ml for large 
cultures and 500µl for small cultures). Cells were allowed to lyse for 
30mins on a shaking incubator at 0°C. Large cultures were then 
subjected to sonication. Following lysis, cells were pelleted by 
centrifugation, supernatants were retained as the soluble protein 
fraction. Cell pellets were resuspended in lysis buffer for protein 
extraction from inclusion bodies. This was achieved by repeated 
washes, pelleting and resuspension in lysis buffer. Inclusion bodies 
were then resuspended in denaturation buffer (Table 5). 
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2.2.12 Yeast protein expression 
Protein expression of p53 in yeast was performed at room temperature 
on a shaking incubator. Large (500ml or 1litre) and small (100ml) 
cultures were inoculated with a single yeast colony containing the p53 
insert in a pTG1895 plasmid. The culture media used was Synthetic 
minimal (SD) media. Cultures were incubated for 3-7days, before cells 
were pelleted by centrifugation in preparation for protein extraction. 
The supernatant media was kept for the purification of any excreted 
protein.  
 
2.2.13 Yeast protein extraction from pelleted cells 
After protein expression, pelleted cells were resuspended in yeast lysis 
buffer, or water. The suspension was frozen at -30°C, thawed and cells 
were pelleted by centrifugation. Cells were then ground using acid 
washed glass beads on a vortex for multiple rounds of 3 minutes, and 
were placed on ice for 5 mins between vortexing. Cells were again 
pelleted and frozen, before repeating the process, (2 more rounds). The 
supernatant resulting from this extraction was carefully decanted, and 
purified by chromatography. 
 
2.2.14 HIS nickel affinity chromatography 
Proteins expressed in inclusion bodies (bacterial expressions) were 
purified by chromatography using a Sigma HIS select nickel affinity gel 
(#p6611), the purification was performed according to manufacturer’s 
instructions under denaturing conditions. 
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Yeast protein expressions were purified by chromatography using a 
Sigma HIS select nickel affinity gel (#p6611), the purification was 
performed according to manufacturer’s instructions under native 
conditions for large scale purification. For cultures > 200ml a 3ml 
chromatography column was used, smaller cultures were purified 
using a 1ml column. All purification took place at room temperature. 
 
2.2.15 Protein concentration 
To concentrate proteins expressed by yeast, so as to make them visible 
by coomassie staining 3 methods were attempted. 
 Freeze drying: Protein samples were freeze dried overnight in a 
Virtis SRC 10 freeze drier. Proteins were then resuspended in 
minimal volume of buffer before SDS PAGE. 
 
 Stirred cell: Protein fractions from HIS purification were 
concentrated using a Millipore stirred ultrafiltration cell, 
according to manufacturer’s instructions. Following 
concentration, proteins were visualised by SDS PAGE. 
 
 Trichloroacetic acid (TCA) precipitation: Protein fractions from 
HIS purification were concentrated by TCA precipitation. An 
equal volume of 20% TCA was added to the sample. Samples 
were then incubated for 30 mins on ice before being pelleted 
(18000g, 4°C, 15mins). After decanting the supernatant, 300µl of 
cold acetone was then added to the pellets before further 
centrifugation for 5mins. The supernatant was removed and the 
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pellets air dried. Samples were resuspended in SDS PAGE sample 
buffer and heated to 65°C for 3mins before loading on an SDS 
gel. 
 
2.2.16 SDS PAGE 
The Laemmli method (Laemmli, 1970) of Sodium Dodecyl Sulphate 
Poly Acrylamide Gel Electrophoresis was used to establish the purity of 
expressed protein as well as to separate protein in preparation for 
transfer to Polyvinylidene fluoride (PVDF) membrane for Western 
blotting. For visualisation of proteins, gels were stained with 
Coomassie Blue overnight and then destained for 2 to 3 hours using 
Coomassie Destain. Pageruler prestained protein ladder (Appendix F) 
was used as a molecular weight marker. Gels were photographed on a 
Bio-Rad GS800 Calibrated Densitometer. For blotting, gels were not 
stained but instead protein was transferred to a PVDF membrane by 
electroblotting.  
 
2.2.17 Western blotting 
Following separation by SDS PAGE, protein samples were transferred 
in a Hoefer mini VE blotting module, to PVDF using Towbin buffer. 
Blots were blocked overnight in blocking buffer (SuperBlock™ Dry 
Blend Blocking buffer (Pierce cat #37545) to prevent non-specific 
binding, and then probed with Anti Dmp53 for 1 hour. A 1:5000 
dilution of primary antibody was used. The primary antibodies 
manufactured by Santa Cruz are polyclonal antibodies raised against 
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Dmp53 (Table: 7). Before incubation with secondary antibody the blot 
was washed twice with PBS tween (0.1 %) for 10 mins per wash. A 
1:10000 dilution of secondary antibody in PBS tween was used to 
detect primary antibody. Incubation in secondary antibody was for 1 
hour. Secondary antibodies were manufactured by Sigma Aldrich and 
are IgG horse radish peroxidase conjugates (Table 8). Membranes were 
then washed 6 times ten minutes per wash with PBS tween, before 
detection. Detection was performed using the SuperSignal® West Pico 
chemiluminescent substrate (Pierce Cat# 37077) as per manufacturers’ 
instructions. Membranes were exposed to Kodak Biomax film, then 
fixed and developed using Axim fixer and. Exposed film was 
photographed on a Bio-Rad GS800 Calibrated Densitometer. All 
incubations and washes were performed with agitation from a platform 
shaker at slow speed.  
 
2.2.18 Extraction of genomic DNA 
Genomic DNA was prepared using a protocol based on the method 
described by Bender et al., (1983). Flies were immobilised using 
Carbon dioxide, collected and homogenised in 100µl grinding buffer. 
After a 30 minute incubation at 75°C, 35 µl of 8 M KOAc was added and 
incubated on ice for 30 minutes to pellet the cellular debris and 
protein. The DNA was then precipitated with isopropanol and washed 
with 70% ethanol before being resuspended in nuclease free water. 
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2.2.19 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify DNA sequences 
for cloning, to make biotin labelled DNA probes for Southern blotting, 
and to detect the presence of specific DNA sequences. Conditions for 
PCR were according to enzyme manufacturer’s instructions. Annealing 
temperature was optimised to ±5°C of primer TM (as specified by the 
primer manufacturer). For colony PCR DNA template was omitted and 
a 0.5mm bacterial clone used.  
 
2.2.20 Southern blotting 
After digestion of genomic DNA from adult flies, hydrolysed DNA was 
run on 1% agarose gel and visualised on a Bio-Rad Geldoc XR. DNA on 
the gels was then depurinated for 10 mins, denatured for 30 mins and 
neutralized for 30 mins by soaking the gel in the respective buffer 
(Table 5) with gentle agitation. DNA was then transferred to a nylon 
membrane by capillary transfer overnight, using Saline Sodium Citrate 
(SSC) as a transfer buffer. Membranes were then crosslinked in 
Stratagene UV crosslinker using the auto crosslink feature (1200000 
µJ). Membranes were then prehybridised in preheated hybridisation 
solution for 30mins at 65°C. Probe (biotin labelled DNA) was then 
added to the solution and the membrane was hybridised overnight at 
65°C. After hybridisation, membranes were washed in a series of 
buffers of increasing stringency. Membranes were rinsed briefly in, 
then washed twice (5 mins each) in low stringency buffer. Then 
washed twice (10 mins each) in medium stringency buffer, and washed 
four times (5 mins each) in high stringency buffer. Hybridisation and 
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washing was carried out in tubes in an Amersham life science 
Hybridisation oven/shaker. The chemiluminescent nucleic acid 
detection module kit was then used to detect DNA bound to probe, 
according to the manufacturer’s instructions, before exposing the 
membrane to film and developed as per Western blotting above.  
2.2.21 Camptothecin treatment of flies 
Adult flies were exposed to 1mM Camptothecin (Sigma #C9911) 
treated baker’s yeast for 48 hours alongside their usual cornmeal feed.  
2.2.22 Extraction of RNA 
The RNA extraction procedure was based on that of  Chomczynski 
(1993), using the TRIzol LS reagent. Larvae and adults (both 
camptothecin treated and untreated) were both homogenized in 500μl 
of TRIzol using an eppendorf pestle homogenizer. RNA was then 
recovered as per the manufacturer’s instructions. The RNA pellet was 
then dissolved at 65°C in 50μl nuclease free water. Samples were snap 
cooled on ice and the concentration was determined on a Nanodrop 
spectrophotometer at 260 nm.  
2.2.23 cDNA synthesis RT PCR SNAMA Oligo(dT) & specific primers 
First strand cDNA synthesis was performed using Fermentas Reverse 
transcriptase, according to the manufacturer’s protocol. Synthesis used 
Oligo(dT) primers in one instance and specific SNAMA reverse primers 
(“BrevSNAMAUtr”, “ArevExon7SNAMA”) in another. cDNA was then 
amplified by PCR. 
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3.  Results 
 
3.1 Gene Structure and isoforms of Dmp53 
Dmp53 is a well-known tumour suppressor protein, whose function is 
affected by numerous cancers. The research used Drosophila as a model 
organism to gain valuable insight into Dmp53 and its interactors. The 
project aims to clone and overexpress Dmp53 protein and look for 
possible interacting proteins. In humans, MDM2 marks Dmp53 for 
degradation by ubiquitination, however, in Drosophila a MDM2 
homolog is yet to be discovered. RBBP6 is a known interactor in other 
species and it is thought that SNAMA, the Drosophila RBBP6 homolog 
would thus also interact. Furthermore, SNAMA is suspected of being a 
Ubiquitin like protein (UBL) and perhaps to play this role in the 
absence of MDM2. In mammals the SNAMA homologue, RBBP6 has 
been shown to enhance the activity of MDM2. 
 
Dmp53 is encoded by the p53 gene found on chromosome 3R of 
Drosophila, its eleven exons form 3 major domains, namely 
Transactivation, DNA binding and Oligomerisation domains. At least 2 
isoforms, a full length Dmp53 and an N-truncated Dmp53 which lacks 
the transactivation domain exist (Dichtel-Danjoy et al., 2012). A third 
isoform which contains only the transactivation domain is also 
identified by Bourdon, (2005). 
A schematic overview of the Dmp53 gene, showing exon positions and 
sizes is presented below (Figure 6).  
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Figure 6: Schematic overview of Drosophila p53 gene structure. 
The figure shows the gene to scale, with the positions and numbering of 
the specific exons. The sizes of the expected exons are shown with their 
positions relative to the gene. An analysis of restriction digestion by 
enzyme which have single cut sites on the gene was carried out using 
DNAman software and the positions of these cut sites relative to the 
gene start are also shown.  
 
44 
 
Southern blotting was performed to establish the gene copy number of 
Dmp53, however, the results were inconclusive. Genomic DNA was 
extracted from adult flies and DNA was hydrolysed using EcoRI and 
combinations SalI, BamHI and XhoI , which were found to cut the strand 
once in the Dmp53 gene region. Agarose gel electrophoresis shows 
successful digestion of genomic DNA (Figure 8). Upon Southern blot 
analysis, only PCR generated Dmp53 shows binding with the probe 
(Figure 8). The protocol was tested by Southern blot analysis of varying 
dilutions of biotin labelled Dmp53 probe, which were generated by PCR 
(Figure 7). 
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Figure 7: Agarose gel of biotin probe and Southern blot thereof. 
100, 80, 60, 40, and 20% dilutions of the biotin probe in water were 
analysed on an agarose gel (A) then transferred to a membrane for 
Southern blotting. The membrane was probed with biotin labelled 
Dmp53 DNA and detected using the chemiluminesence detection 
module kit. The blot (B) confirms that the protocol was successful.  
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Figure 8: Digestion of genomic DNA and Southern blot thereof.  
(A) Lanes 1 to 3 show the presence and digestion of genomic DNA in 
preparation for Southern blotting. Lane 1 = EcoRI digestion, 2 = SalI 
and BamHI digestion, 3 = SalI and XhoI digestion. Lane 4 shows a 
Dmp53 control. The Southern blot alongside (B) shows only, probe 
binding to the control insert DNA.  
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3.2 Heterologous expression of Dmp53 in E. coli 
E. coli BL21 (DE3) pLys S, was transformed with, a clone of Dmp53 
insert in pET41a plasmid. The transformed cells were grown to an 
optical density of 0.6 in LB media and protein expression was induced 
using IPTG. 2, 4 and 6 hour inductions were performed and an 
uninduced sample kept. After induction cells were lysed chemically and 
proteins re-suspended. Proteins in inclusion bodies were re-suspended 
in denaturation buffer. SDS PAGE confirmed that heterologous 
expression had taken place. Subsequently, Western blot analysis was 
used to probe for Dmp53 (Figure 9). After induction for 6 hours a 
fraction of the supernatant (soluble proteins) was purified by 
chromatography to determine if Dmp53 was present (Figure 10). Both 
of these results clearly show that Dmp53 is expressed as an insoluble 
inclusion body, irrespective of the time period of protein expression 
after induction. Specifically, Figure 9 shows Dmp53 detected only in 
pellet fractions in 2, 4 and 6 hr expressions and Figure 10 shows no 
eluted soluble protein 6 hours after induction. It is notable that the 
cross reacting proteins detected may be foreign to E. coli, as they also 
appear in pellet fractions. The lack of an untransformed E. coli control 
leaves this question unanswered. 
  
48 
 
 
Figure 9: Western blot analysis of Dmp53 in soluble and insoluble 
fractions of expressed protein. After heterologous expression of 
Dmp53 in E. coli, proteins were extracted and inclusion bodies re-
suspended. Crude extracts were probed for Dmp53 using anti Dmp53 
rabbit primary antibody, and anti-rabbit peroxidase secondary 
antibody. Odd numbered lanes contain soluble protein fractions. Even 
numbered lanes contain re-suspended pellet fractions (inclusion 
bodies). Lane 1 and 2 contain uninduced samples. Lanes 3-4; 5-6; and 
7-8; contain 2, 4 and 6 hour induction samples respectively. Lane 9 
contains previously prepared purified heterologously expressed 
Dmp53 as a control. The Figure shows that Dmp53 is expressed as an 
insoluble inclusion body, irrespective of the time period of protein 
expression after induction. 
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Figure 10: Purified soluble protein fraction from heterologous 
expression in E. coli, 6 hours after induction. The crude protein 
extract was purified by HIS chromatography. No Dmp53 is present in 
the elution fractions. This once again shows that Dmp53 is expressed as 
insoluble inclusion bodies in E. coli. 
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3.3  Protein expression and purification in Yeast 
The yeast plasmid pTG1895, was prepared on a large scale. 
Subsequently some plasmid was restricted with EcoRI to determine if 
preparation was successful. The presence of two bands (at positions 
7000bp and 2800bp) confirms that pTG1895 has the expected size and 
was linearised as compared to a typical 3 band migration pattern of 
undigested plasmid (Figure 11). The remainder of the plasmid was 
linearised and dephosphorylated in preparation for cloning. Dmp53 in 
pET41a was also prepared. PCR was performed on the Dmp53 in 
pET41a with primers designed to amplify the Dmp53 insert. These 
primers change the restriction sites to those of pTG1895 so as to clone 
this amplified insert into pTG1895 in the correct frame and orientation. 
Figure 12, shows the successful amplification of Dmp53 insert (lane1), 
which is slightly larger in size when compared to the original fragment 
(lane2). This is due to the inclusion of a HIS tag and some upstream 
sequence from the pET41a vector. 
 
The amplified insert was ligated into the TA cloning site of pGEM-T 
Easy plasmid and subsequently E. coli was transformed with the 
plasmid. Bacterial clones were screened for successful transformants, 
using blue white screening and then using restriction digestion analysis 
(with HindIII and SalI, which form the cloning site in pTG1895).  
 
Plasmid DNA from successfully transformed clones was purified on a 
large scale in preparation for DNA recovery from an agarose gel. This 
was subsequently ligated into pTG1895, and bacteria transformed. 
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Clones were screened for successful transformants and plasmid DNA 
was isolated and purified on a large scale.  
 
Figure 11: Confirmation of plasmid preparation by restriction 
digest. Lane two contains plasmid hydrolysed with EcoRI. Two bands 
of the expected size are present, confirming that pTG1895 has been 
successfully prepared. 
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Figure 12: Dmp53 insert was successfully amplified by 
polymerase chain reaction, shown in lane 1. Lane 2 shows a control 
PCR of Dmp53 using different primers and template. The insert was gel 
purified, hydrolysed and ligated into pGem-T Easy for large scale 
preparation before being ligated into yeast plasmid pTG1895 in further 
reactions. 
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Yeast (Tgy 48-1) was then cultured and made competent. Following 
this the competent yeast was immediately transfected with the purified 
plasmid containing the Dmp53 insert. The transfection followed a 
modified Lithium Acetate method. Colonies which grew on selective 
media, were then screened by colony PCR, to confirm the presence of 
the Dmp53 insert. Clones that have taken up Dmp53 show a band at 
1000bp as confirmed by a positive control (Figure 13).  
 
Having confirmed the presence of Dmp53 insert in clones 1 and 4, 
these clones were cultured in SD media, for the expression of Dmp53 
protein. After growing to a suitable OD, the yeast was pelleted and re-
suspended. Protein extracts were purified using HIS-nickel affinity 
chromatography. The cloned Dmp53 insert (1020bp) gives rise to a 
340 aa sequence, which equates to a protein approximately 37.5 kDa in 
size, however, Dmp53 could not initially be visualized by SDS PAGE, 
where gels appeared blank or showed very faint staining in lanes of 
interest. To determine if protein expression was indeed occurring, 
transformed and untransformed yeast were cultured. Crude protein 
extracts from these cultures were concentrated using a Millipore 
stirred cell, SDS PAGE showed that some protein was being expressed 
and secreted by the yeast, however, Western blot analysis could not 
positively identify Dmp53 due to non-specific binding (Figure 14). 
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Figure 13: Colony PCR analysis of transformed clones to detect 
clones with Dmp53 insert, clone 1 and 4 show the presence of insert, 
correlating to the positive control (+), a PCR amplification of Dmp53 
from bacterial plasmid. The negative control (-), pTG1895 without 
insert, shows no amplification as expected.  
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Figure 14: Crude extracts from Protein expressions of 
transformed and untransformed yeast concentrated by stirred 
cell, and Western blot thereof. SDS analysis after coomassie blue 
staining, shows that transformed yeast cultured in S Synthetic minimal 
(SD) media is expressing protein, lane 2. Untransformed yeast cultured 
in SD media (lane3) and YPG media (lane4) also express some protein, 
but far less as compared to Transformed yeast. Lanes 1 contained the 
molecular weight marker. Lane 5 contained Dmp53 purified from 
bacterial protein expression as a control. Western blot analysis shows 
non-specific binding of the Dmp53 antibody. This experiment cannot 
positively confirm that Dmp53 is being expressed and that it is being 
secreted. 
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Upon experimentation, it was found that the yeast was expressing 
Dmp53 in very low concentrations. SDS PAGE gels of proteins from 
expression cultures, some in excess of 1 litre, showed faint bands, or 
none whatsoever, after staining. Expressed proteins only became 
visible on gels after TCA precipitation (Figure 15b). Also the yeast 
expression system was retaining the protein in the cytosol as opposed 
to exporting it, as per the experimental design, analyses by SDS PAGE 
showed expressed Dmp53 in cytosolic fractions (Figure 15b) and not in 
the media (Figure 15a).  
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Figure 15: SDS PAGE to visualise Dmp53. Cultures of clones 1 and 4 
were grown. Supernatant (A) and mechanically lysed yeast pellet (B), 
were HIS purified, and then concentrated by TCA precipitation. After 
coomassie blue staining, no Dmp53 is visible in the supernatant (A), 
proving retention of the protein. (B) shows that both clones 1 and 4 
have retained Dmp53 in their cytosol. 
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TCA precipitation, causes denaturation of proteins, therefore proteins 
were expressed and purified again. In an attempt to increase protein 
concentration of the expression, a protease inhibitor cocktail was 
included in the culture media. Proteins were expressed in 50ml 
cultures grown at room temperature for five days. After expression, the 
media was kept aside and protein extracted from the cells by 
mechanical lysis using acid washed glass beads. Both the supernatant 
media and the cell extract were then purified by HIS chromatography. 
Figure 16 shows a successful purification and a suspected Dmp53 
eluting in the cell fraction, again confirming the retention instead of 
excretion of the protein. The size of the protein is approximately 
37kDa, which equates to an insert size of roughly 1020aa, equal to the 
cloned Dmp53 insert. This is also the same size protein that became 
visible after TCA precipitation, as shown in Figure 15b.  
 
Once again Western blot analysis of the gel could not positively confirm 
the identity of Dmp53, due to non-specific binding, as seen in Figure 17. 
The Dmp53 antibody binds to most proteins present including the 
molecular weight marker. 
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Figure 16: Yeast expression with the inclusion of protease 
inhibitors. Dmp53 is visible in elution fractions of the coomassie blue 
stained SDS PAGE gel. Lane 1-4 contain the media supernatant after 
purification by HIS chromatography, lanes 5-9 contain proteins 
extracted from the cell pellet and purified by HIS chromatography 
(crude extract, flow-through, wash and elution fractions respectively).  
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Figure 17: Non-specific binding of Dmp53 antibodies during 
western blot analysis on successive exposures of membrane to film. 
The above exposure times were 5 seconds, and 10 seconds 
respectively.  
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3.4 Gene structure and isoforms of SNAMA 
A recent update of the flybase genome database theoretically identified 
a second SNAMA transcript, referred to as SNAMA B. The SNAMA 
transcripts have 5ˊ UTRs which start at different sites and share exons 
1 through 4. There is a minor difference in exon 5 where SNAMA B, the 
shorter transcript, stops and SNAMA A continues for a few base pairs. 
SNAMA A has a further 3 exons after this (Table 12). The SNAMA gene 
structure is depicted in Figure 18. 
 
 
Figure 18: A schematic overview of the gene structure of the 
SNAMA A and B isoforms. Untranslated gene regions are shown in 
blue while exons are shown in yellow. SNAMA A and B share 5 exons. 
SNAMA A, the full length SNAMA isoform has a further 3 exons 
(adapted from flybase (St Pierre et al., 2014)). 
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Table 12: A Comparison of the SNAMA A and B gene structure. After 
bioinformatic analysis of the SNAMA A and B gene structure and 
sequence results were tabulated to highlight differences and 
commonalities. Differences found are shown in red, and common 
introns and exons are shown in yellow. 
 RA  RB  
5ˊUTR 4129-4225  4197-4634 5ˊ UTR 
-    - 
5ˊUTR 5055-5073  5055-5073 5ˊUTR 
Exon 5074-5239 165 5074-5239 Exon 
Intron    Intron 
Exon 5299-5533 234 5299-5533 Exon 
Intron    Intron 
Exon 5588-6066 478 5588-6066 Exon 
Intron    Intron 
Exon 6127-6401 274 6127-6401 Exon 
Intron    Intron 
Exon 6465-6790 325/329 6465-6794 Exon 
Intron   6795-7035 3ˊUTR 
Exon 7079-7228 209   
Intron     
Exon 7289-7582 293   
Intron     
Exon 7645-9415 1770   
3ˊUTR 9416-9537    
     
 Differences    
 
Common introns and 
exons 
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After bioinformatic analysis of the SNAMA gene region and translation, 
we hypothesize that transcript B arises from alternative splicing. The 
SNAMA A&B transcripts occur in shifted open reading frames through 
alternative splicing introducing a stop codon before exon 6 (Figure 19). 
The transcripts also differ in their 5ˊ UTR start sites (Figure 20). Figure 
20 shows the aligned amino acid sequences of SNAMA A and SNAMA B 
highlighting conserved functional domains. 
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1     TCGGAGTTTTTATGTGCTTGCAGAGTAGTGTAAGTAATTGCTATTTTTGTGCCAGCTGCT 
     
61    TGCCGGTAGTAAACAACGCGCGTGAACTGTGATGCCTTGCAATCCTCAGCGCAATTCAAG 
       
121   TGCGGTTTAAGTCCGAACGACCCAAGAAACCCGAAGTGTACGTACATATGTATGTTTTCG 
       
181   CGTGTGTATTTTTATGCACATGCAATTCTATGCTGCTGCCATGCAAAGGTGCAAAAAATG 
       
241   CGAAATGCAAATATCGTTCACAGAATGCCCATTGATCTGACCGGATTTTAGGTGGCACAT 
       
301   ACGCATATGCATATAGCATGTTCCCGGAATTGTGCAACTTCGCATACATACATATGTAAT 
      
361   GTCTTATGTTGGCATAATTATCCGCTGTTCAAGGGAAGTGCATGGTGCAAATCGGGAATC 
      
421   TATATTCGGCATACTTTGATTTCTTTCATATGCAACTATGTCGGTACACTATAAATTTAA 
1                                           M  S  V  H  Y  K  F  K  
 
481   GAGTACACTCAACTTTGATACAATTACTTTTGATGGACTTCACATTTCTGTCGGGGACTT 
9       S  T  L  N  F  D  T  I  T  F  D  G  L  H  I  S  V  G  D  L  
 
541   AAAAAGGGAGATTGTGCAGCAGAAGCGACTGGGCAAAATCATCGACTTTGATCTCCAAAT 
29      K  R  E  I  V  Q  Q  K  R  L  G  K  I  I  D  F  D  L  Q  I  
 
601   AACAAATGCGCAGAGTAAAGAAGAATACAAGGACGATGGGTTCCTTATTCCCAAAAACAC 
49      T  N  A  Q  S  K  E  E  Y  K  D  D  G  F  L  I  P  K  N  T  
 
661   AACGCTGATCATATCGCGCATCCCCATCGCCCATCCCACAAAAAAGGGCTGGGAGCCACC 
69      T  L  I  I  S  R  I  P  I  A  H  P  T  K  K  G  W  E  P  P  
 
721   AGCAGCAGAAAATGCCTTTTCGGCGGCGCCTGCCAAGCAGGACAACTTCAACATGGACCT 
89      A  A  E  N  A  F  S  A  A  P  A  K  Q  D  N  F  N  M  D  L  
 
781   GTCCAAAATGCAAGGCACGGAGGAGGACAAAATCCAGGCCATGATGATGCAGAGCACAGT 
109     S  K  M  Q  G  T  E  E  D  K  I  Q  A  M  M  M  Q  S  T  V  
 
841   CGACTATGATCCTAAGACGTACCATCGTATTAAAGGACAATCGCAAGTGGGAGAAGTTCC 
129     D  Y  D  P  K  T  Y  H  R  I  K  G  Q  S  Q  V  G  E  V  P  
 
901   CGCATCCTACCGATGCAACAAATGCAAGAAAAGCGGACACTGGATCAAAAACTGTCCCTT 
149     A  S  Y  R  C  N  K  C  K  K  S  G  H  W  I  K  N  C  P  F  
 
961   TGTGGGGGGAAAGGACCAGCAAGAGGTCAAACGGAATACTGGTATTCCGCGGTCTTTCCG 
169     V  G  G  K  D  Q  Q  E  V  K  R  N  T  G  I  P  R  S  F  R  
 
1021  CGACAAGCCAGATGCGGCTGAGAACGAATCAGCCGATTTTGTGCTGCCTGCTGTACAAAA 
189     D  K  P  D  A  A  E  N  E  S  A  D  F  V  L  P  A  V  Q  N  
 
1081  CCAAGAGATACCGGAGGATCTGATATGCGGCATATGCCGAGATATATTCGTCGATGCTGT 
209     Q  E  I  P  E  D  L  I  C  G  I  C  R  D  I  F  V  D  A  V  
 
1141  CATGATACCCTGCTGCGGAAGTTCCTTTTGTGACGACTGTGTGCGAACCTCCTTATTGGA 
229     M  I  P  C  C  G  S  S  F  C  D  D  C  V  R  T  S  L  L  E  
 
 
1201  GTCAGAGGATAGTGAGTGCCCCGATTGCAAGGAGAAGAACTGTTCGCCTGGCTCCCTGAT 
249     S  E  D  S  E  C  P  D  C  K  E  K  N  C  S  P  G  S  L  I  
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1261  ACCTAATCGGTTCTTGAGGAATTCGGTGAACGCCTTTAAAAATGAGACTGGGTATAACAA 
269     P  N  R  F  L  R  N  S  V  N  A  F  K  N  E  T  G  Y  N  K  
 
1321  AAGCGCGGCTAAGCCAGCTGCAGTAAAAAATGAGGAAAAACCTCCTGTTGAAAAAGAAGT 
289     S  A  A  K  P  A  A  V  K  N  E  E  K  P  P  V  E  K  E  V  
 
1381  GGAGAAAAAGCCAGTCGCGGAGGTGGAACCCGAAGAGACTGAGGTGAAACCTGAAAAGCA 
309     E  K  K  P  V  A  E  V  E  P  E  E  T  E  V  K  P  E  K  Q  
 
1441  AAAAGAATCCGAAACCAATGGCAGTAATCCGCCAAAATCGGAATCTCCAGAGCCTCCCGC 
329     K  E  S  E  T  N  G  S  N  P  P  K  S  E  S  P  E  P  P  A  
 
1501  AACCACAGAACCATCACAGAAGGAGAAAGATAAATATGATTCAGACTACGAGGATAACAT 
349     T  T  E  P  S  Q  K  E  K  D  K  Y  D  S  D  Y  E  D  N  I  
 
1561  TACCATAAAAATGCCCCAGCCTGCAGCTGATTCTACAACAGTGCCCAGCAAAAGATCCCC 
369     T  I  K  M  P  Q  P  A  A  D  S  T  T  V  P  S  K  R  S  P  
 
1621  CAGTTATTCCCACAGAAGTGAATCCTCTCATCGACGGGACAGGTCGGATTATGTTTCCGA 
389     S  Y  S  H  R  S  E  S  S  H  R  R  D  R  S  D  Y  V  S  D  
 
1681  TCACGATCACAAGCACCAACGTCCATCAAAATCGGAGTCTGTTAACAAGGATCGCAGTCT 
409     H  D  H  K  H  Q  R  P  S  K  S  E  S  V  N  K  D  R  S  L  
 
1741  CCTGCCCTTGCCCATTGGCACCCTGCCTAGCTACCAGGGCCACATGATGGCCGAATCAGA 
429     L  P  L  P  I  G  T  L  P  S  Y  Q  G  H  M  M  A  E  S  E  
 
1801  AGAAGCTCGTCGATCGAGTGCCTATAAGCCCCCTTATATGCAAATGCAGCGGGGCCCACC 
449     E  A  R  R  S  S  A  Y  K  P  P  Y  M  Q  M  Q  R  G  P  P  
 
1861  TCCTATGCACATGATGAGTCACCACATGCCAGCCTACAACAACGGGTTTAACAACATGGG 
469     P  M  H  M  M  S  H  H  M  P  A  Y  N  N  G  F  N  N  M  G  
 
1921  ACAGAGGCCTCCCCTCAGGTAGGTTTCTTTTCCACCCGTCCGGATCCCGCTACCATGTGG 
489     Q  R  P  P  L  R  *   
 
1981  ATCGAGTCAAGTGTCGAGGCCACTGGAACTCCGAGGTGTTGACGAGTCCATACGCAGCCG 
      
2041  GTCCTGCCTGATCTCAATATTTTTAAGTTCCAACAGAGACTATACACACACACTAGTTAA 
      
2101  GAGTAATTTAAGCTCTGGGCTCTGCGCCTTTATGCTTTGTTGAATATTGGTTATTCCTAA 
      
2161  TTAAAACAGTATTGCTTACAATC 
      
 
Figure 19: SNAMA B sequence with translation. The ORF appears in 
translation frame 2. Exons shared with SNAMA A (Figure 20) are 
highlighted in green. The stop codon is highlighted in red. This is the 
alternative splice site where the addition of further exons gives rise to 
SNAMA A. 
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1    GCATTTCACATCTCTGGGGCTTTGGCGTCACGTTCGCATCTCTAGTAAATTGGAAAAAAA 
        
61   TAAAATCGTCGGAGTTTTTATGTGCTTGCAGAGTAGTATTTCTTTCATATGCAACTATGT 
1                                                             M  S 
 
121  CGGTACACTATAAATTTAAGAGTACACTCAACTTTGATACAATTACTTTTGATGGACTTC 
3       V  H  Y  K  F  K  S  T  L  N  F  D  T  I  T  F  D  G  L  H 
 
181  ACATTTCTGTCGGGGACTTAAAAAGGGAGATTGTGCAGCAGAAGCGACTGGGCAAAATCA 
23      I  S  V  G  D  L  K  R  E  I  V  Q  Q  K  R  L  G  K  I  I 
 
241  TCGACTTTGATCTCCAAATAACAAATGCGCAGAGTAAAGAAGAATACAAGGACGATGGGT 
43      D  F  D  L  Q  I  T  N  A  Q  S  K  E  E  Y  K  D  D  G  F 
 
301  TCCTTATTCCCAAAAACACAACGCTGATCATATCGCGCATCCCCATCGCCCATCCCACAA 
63      L  I  P  K  N  T  T  L  I  I  S  R  I  P  I  A  H  P  T  K 
 
361  AAAAGGGCTGGGAGCCACCAGCAGCAGAAAATGCCTTTTCGGCGGCGCCTGCCAAGCAGG 
83      K  G  W  E  P  P  A  A  E  N  A  F  S  A  A  P  A  K  Q  D 
 
421  ACAACTTCAACATGGACCTGTCCAAAATGCAAGGCACGGAGGAGGACAAAATCCAGGCCA 
103     N  F  N  M  D  L  S  K  M  Q  G  T  E  E  D  K  I  Q  A  M 
 
481  TGATGATGCAGAGCACAGTCGACTATGATCCTAAGACGTACCATCGTATTAAAGGACAAT 
123     M  M  Q  S  T  V  D  Y  D  P  K  T  Y  H  R  I  K  G  Q  S 
 
541  CGCAAGTGGGAGAAGTTCCCGCATCCTACCGATGCAACAAATGCAAGAAAAGCGGACACT 
143     Q  V  G  E  V  P  A  S  Y  R  C  N  K  C  K  K  S  G  H  W 
 
601  GGATCAAAAACTGTCCCTTTGTGGGGGGAAAGGACCAGCAAGAGGTCAAACGGAATACTG 
163     I  K  N  C  P  F  V  G  G  K  D  Q  Q  E  V  K  R  N  T  G 
 
661  GTATTCCGCGGTCTTTCCGCGACAAGCCAGATGCGGCTGAGAACGAATCAGCCGATTTTG 
183     I  P  R  S  F  R  D  K  P  D  A  A  E  N  E  S  A  D  F  V 
 
721  TGCTGCCTGCTGTACAAAACCAAGAGATACCGGAGGATCTGATATGCGGCATATGCCGAG 
203     L  P  A  V  Q  N  Q  E  I  P  E  D  L  I  C  G  I  C  R  D 
 
781  ATATATTCGTCGATGCTGTCATGATACCCTGCTGCGGAAGTTCCTTTTGTGACGACTGTG 
223     I  F  V  D  A  V  M  I  P  C  C  G  S  S  F  C  D  D  C  V 
 
841  TGCGAACCTCCTTATTGGAGTCAGAGGATAGTGAGTGCCCCGATTGCAAGGAGAAGAACT 
243     R  T  S  L  L  E  S  E  D  S  E  C  P  D  C  K  E  K  N  C 
 
901  GTTCGCCTGGCTCCCTGATACCTAATCGGTTCTTGAGGAATTCGGTGAACGCCTTTAAAA 
263     S  P  G  S  L  I  P  N  R  F  L  R  N  S  V  N  A  F  K  N 
 
961  ATGAGACTGGGTATAACAAAAGCGCGGCTAAGCCAGCTGCAGTAAAAAATGAGGAAAAAC 
283     E  T  G  Y  N  K  S  A  A  K  P  A  A  V  K  N  E  E  K  P 
 
1021 CTCCTGTTGAAAAAGAAGTGGAGAAAAAGCCAGTCGCGGAGGTGGAACCCGAAGAGACTG 
303     P  V  E  K  E  V  E  K  K  P  V  A  E  V  E  P  E  E  T  E 
 
1081 AGGTGAAACCTGAAAAGCAAAAAGAATCCGAAACCAATGGCAGTAATCCGCCAAAATCGG 
323     V  K  P  E  K  Q  K  E  S  E  T  N  G  S  N  P  P  K  S  E 
 
1141 AATCTCCAGAGCCTCCCGCAACCACAGAACCATCACAGAAGGAGAAAGATAAATATGATT 
343     S  P  E  P  P  A  T  T  E  P  S  Q  K  E  K  D  K  Y  D  S 
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1201 CAGACTACGAGGATAACATTACCATAAAAATGCCCCAGCCTGCAGCTGATTCTACAACAG 
363     D  Y  E  D  N  I  T  I  K  M  P  Q  P  A  A  D  S  T  T  V 
 
1261 TGCCCAGCAAAAGATCCCCCAGTTATTCCCACAGAAGTGAATCCTCTCATCGACGGGACA 
383     P  S  K  R  S  P  S  Y  S  H  R  S  E  S  S  H  R  R  D  R 
 
1321 GGTCGGATTATGTTTCCGATCACGATCACAAGCACCAACGTCCATCAAAATCGGAGTCTG 
403     S  D  Y  V  S  D  H  D  H  K  H  Q  R  P  S  K  S  E  S  V 
 
1381 TTAACAAGGATCGCAGTCTCCTGCCCTTGCCCATTGGCACCCTGCCTAGCTACCAGGGCC 
423     N  K  D  R  S  L  L  P  L  P  I  G  T  L  P  S  Y  Q  G  H 
 
1441 ACATGATGGCCGAATCAGAAGAAGCTCGTCGATCGAGTGCCTATAAGCCCCCTTATATGC 
443     M  M  A  E  S  E  E  A  R  R  S  S  A  Y  K  P  P  Y  M  Q 
 
1501 AAATGCAGCGGGGCCCACCTCCTATGCACATGATGAGTCACCACATGCCAGCCTACAACA 
463     M  Q  R  G  P  P  P  M  H  M  M  S  H  H  M  P  A  Y  N  N 
 
1561 ACGGGTTTAACAACATGGGACAGAGGCCTCCCCTCAGCTATGTGCCGTATCAAAACCAAT 
483     G  F  N  N  M  G  Q  R  P  P  L  S  Y  V  P  Y  Q  N  Q  S 
 
1621 CCGTACACCCAATGCGTGCGCCGTACGGATCTGCAGGCGGAGGTATGAATATGAATATGT 
503     V  H  P  M  R  A  P  Y  G  S  A  G  G  G  M  N  M  N  M  S 
 
1681 CACAACCATTTCAGTCCCCAAATTTAGCCTCGATATACCAAGGGGTGGCAGCGAAGGTCG 
523     Q  P  F  Q  S  P  N  L  A  S  I  Y  Q  G  V  A  A  K  V  G 
 
1741 GTTCCGGTCCCATTGACGATCCGTTGGAGGCCTTCAATCGCATCATGAAGGAGAAGGAGC 
543     S  G  P  I  D  D  P  L  E  A  F  N  R  I  M  K  E  K  E  R 
 
1801 GGAAGAAGGTGGACCGCTTTCGAAGCTCTGACCGCCACAGGTCAAGGTCCCCGGATAGAC 
563     K  K  V  D  R  F  R  S  S  D  R  H  R  S  R  S  P  D  R  Q 
 
1861 AAAGGCACCGCTTTAAGTCTCCCATGTACGAAAAGGACAACTCCAGGGATAATCTCAAGG 
583     R  H  R  F  K  S  P  M  Y  E  K  D  N  S  R  D  N  L  K  D 
 
1921 ACAAAAGACCGCGATCCCGGGAAAGGAAGCGAGAACATAGCTACGAACGGCATATACGCC 
603     K  R  P  R  S  R  E  R  K  R  E  H  S  Y  E  R  H  I  R  H 
 
1981 ACCCTCGTTCTAGTCGCCAGCCGAATGATGGCTCTAAGTCCCCAGGTGGCAGAATCAAAA 
623     P  R  S  S  R  Q  P  N  D  G  S  K  S  P  G  G  R  I  K  R 
 
2041 GATCTGGACATCGTCGCTCTGCATCTCCAAAGCCGGGCTACAAGAGTGATTACAGAGACA 
643     S  G  H  R  R  S  A  S  P  K  P  G  Y  K  S  D  Y  R  D  K 
 
2101 AGCCGTACAACAAGCCTAGTGCTCCCAAAACGGAGGCAGTTGAGCCTCCTCCCCCCGGAT 
663     P  Y  N  K  P  S  A  P  K  T  E  A  V  E  P  P  P  P  G  F 
 
2161 TCGAGCCGTTGCAGCTGACGGATGAAGACGGCTACAGGAACAAGCACCCGACCAGTTCGG 
683     E  P  L  Q  L  T  D  E  D  G  Y  R  N  K  H  P  T  S  S  E 
 
2221 AAGCATCACAAAGCAGCAAGGGTGATAGCAGCAAGAAGAGAGGGGAAAACAGGCACGAAG 
703     A  S  Q  S  S  K  G  D  S  S  K  K  R  G  E  N  R  H  E  E 
 
2281 AGGCGCCACGAAAGAGGCACAGGTCTCGCAGCATTAGCAAGGAACCGAAGCCGAATGACA 
723     A  P  R  K  R  H  R  S  R  S  I  S  K  E  P  K  P  N  D  S 
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2341 GCAACTACAGGAGCCTGACTCCACCAGCAAAGATCACCACACCGAAAATGACTGCTGCCC 
743     N  Y  R  S  L  T  P  P  A  K  I  T  T  P  K  M  T  A  A  Q 
 
2401 AGTTGAGGCAACGCGAAAGTTCACCGAAGACGCCGGAAAAGAGTCACGACGATTATCTGA 
763     L  R  Q  R  E  S  S  P  K  T  P  E  K  S  H  D  D  Y  L  T 
 
2461 CCGCGAAGGCCAGAATTATGGCCTCCCAGCCCGTCATCAACGACACGGAAATGGAGACCA 
783     A  K  A  R  I  M  A  S  Q  P  V  I  N  D  T  E  M  E  T  N 
 
2521 ATGTGGGCAAGGAGAACAAGGCCAAGAGTCCGTTGTCAAAAGATCGCAAGAAGAAGAAGA 
803     V  G  K  E  N  K  A  K  S  P  L  S  K  D  R  K  K  K  K  K 
 
2581 AGGACAAGGACAAGGCTGAGCGCAAGAAAAACAAGAAGGACAAGCGCGCTAAGAAGGAGA 
823     D  K  D  K  A  E  R  K  K  N  K  K  D  K  R  A  K  K  E  K 
 
2641 AAGGGGATCGCCAGAAGAAGAGCTCCTCAGTTAATCGATCTGACTCGGATATTAACAACA 
843     G  D  R  Q  K  K  S  S  S  V  N  R  S  D  S  D  I  N  N  S 
 
2701 GCTCACTAATGAACGAGTCAAATTATAAAGTATTGTCTCCCAGGGCTCAAAGTCCCAGCA 
863     S  L  M  N  E  S  N  Y  K  V  L  S  P  R  A  Q  S  P  S  I 
 
2761 TTGAGATCAATGCGGCTCAACTTTCCCCTACTCACAACGCTACTGAAAACGTTAATCCGA 
883     E  I  N  A  A  Q  L  S  P  T  H  N  A  T  E  N  V  N  P  K 
 
2821 AGAGTCATTCCATCCTTACTGTGGGTGCTGCTAGCGACGATAATCTTGGCCCAAGAAGCA 
903     S  H  S  I  L  T  V  G  A  A  S  D  D  N  L  G  P  R  S  K 
 
2881 AACTCAGCGAGGCTAATTCTGTCAATCTATCCAAATGGGAAATCGACGAGAATATCTTAG 
923     L  S  E  A  N  S  V  N  L  S  K  W  E  I  D  E  N  I  L  G 
 
2941 GTTTGGAGGATTCCTCCAAAAAAGCTGCCGGGGCCTCCGACGATCCGTCGGAAATAACTT 
943     L  E  D  S  S  K  K  A  A  G  A  S  D  D  P  S  E  I  T  S 
 
3001 CAGACGTCCTGCGAAAGGCTGAGAACGCAATATTTGCAAAGGCTATTAATGCCATCAGGC 
963     D  V  L  R  K  A  E  N  A  I  F  A  K  A  I  N  A  I  R  P 
 
3061 CTATGGAGTTTCAAGTTATTATCAATTCCAAGGACAACAGCAAGGACCGCTCCGTAGTTC 
983     M  E  F  Q  V  I  I  N  S  K  D  N  S  K  D  R  S  V  V  R 
 
3121 GAAGTGACAAGGATCGCTCCTCCTCACCCAGGCGTAACAACAGCAGCAGGTCGGTAAAGG 
1003    S  D  K  D  R  S  S  S  P  R  R  N  N  S  S  R  S  V  K  D 
 
3181 ATAGGCTGGGCACCAAGATTTCCAATGATAGAAGCCGTTCGCGAGACAAGTCGAAGGGCA 
1023    R  L  G  T  K  I  S  N  D  R  S  R  S  R  D  K  S  K  G  R 
 
3241 GGCGCCGGGCCGCAAGGAGCTCCGACGACGATGCGAACCGCGGCAGGTCGGATCGTCATG 
1043    R  R  A  A  R  S  S  D  D  D  A  N  R  G  R  S  D  R  H  G 
 
3301 GCAGCCGGAAGAGGGACAACAGATCCCGCGACAGGGCGGCGCCTTCAGAGAAGAGGCAGG 
1063    S  R  K  R  D  N  R  S  R  D  R  A  A  P  S  E  K  R  Q  E 
 
3361 AGCGTTCGTACAAGCGAAGCTCGCCGGAGGACGACAAGCTGAGGCGCCAGAACAAGGAAC 
1083    R  S  Y  K  R  S  S  P  E  D  D  K  L  R  R  Q  N  K  E  Q 
 
3421 AGTCCGAATCCAAGCACGGAAAGCATGATCAAAACAATAGCGACGACTCGGATCGGAGGG 
1103    S  E  S  K  H  G  K  H  D  Q  N  N  S  D  D  S  D  R  R  A 
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3481 CGGCCAAAAACACCAAGTCCAGCGACAGCCGAGTGGTCTCCTCTGTAACAGCCGTGGTTG 
1123    A  K  N  T  K  S  S  D  S  R  V  V  S  S  V  T  A  V  V  A 
 
3541 CTCCTCCCAAACCCTGTCGTCCAGACAACCCGTTCCGCAAGTTCGTCGACACCAGTTCGT 
1143    P  P  K  P  C  R  P  D  N  P  F  R  K  F  V  D  T  S  S  S 
 
 
3601 CGAGCAGCTTAGTTGTAAAATATGATAACACGATACAGAAGGAGGGCGCGTCCTCGGACA 
1163    S  S  L  V  V  K  Y  D  N  T  I  Q  K  E  G  A  S  S  D  N 
 
3661 ACGGCATGGAGCACAGGAAGCAGAGGGATAAGAAGCTGAAGAAACATTCAAAATATTCGT 
1183    G  M  E  H  R  K  Q  R  D  K  K  L  K  K  H  S  K  Y  S  S 
 
3721 CAACCGATTCGTTGAAGAGCGAGAAGCGCAAGGATCCGAAGAGCAAAAAGAAGAGCAAGA 
1203    T  D  S  L  K  S  E  K  R  K  D  P  K  S  K  K  K  S  K  I 
 
3781 TTTTGAAGAAGAAGAAAAAATCAAAGAAGTAGGTTACGGTAGGCTACGAGATAAGAATGA 
1223    L  K  K  K  K  K  S  K  K  *   
 
3841 TATAAATATTGAAGATTAATGTGTACAAATCAAAGATTTTTAATGTATGTATTTATCATG 
     
3901 CAACTATAAGTATACAAATAAAACAGAACTACTC 
     
 
Figure 20: SNAMA A sequence with translation. The ORF appears in 
translation frame 3. Exons shared with SNAMA B (Figure 19) are 
highlighted in yellow. The alternative splice site is highlighted in 
magenta, and the stop codon in red. 
 
On alignment of protein sequences of SNAMA A and B with Human 
RBBP6 and DWNN, we can map the presence of possible functional 
domains in the isoforms. Although aligning the sequences does not 
show high conservation of residues across species, certain key residues 
are present with some variation. Figure 21 highlights the probable 
locations of functional domains on SNAMA A and B. Figure 22 presents 
the possible domain structure of these isoforms in a schematic 
overview. 
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                  10        20        30        40        50        60     
         ....|....|....|....|....|....|....|....|....|....|....|....|    
SNAMA-B  MSVHYKFKSTLNFDTITFDGLHISVGDLKREIVQQKRLGKIIDFDLQITNAQSKEEYKDD   DWNN DOMAIN CONSERVED 
SNAMA-A  MSVHYKFKSTLNFDTITFDGLHISVGDLKREIVQQKRLGKIIDFDLQITNAQSKEEYKDD                     
                  70        80        90       100       110       120         
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  GFLIPKNTTLIISRIPIAHPTKKGWEPPAAENAFSAAPAKQDNFNMDLSKMQGTEEDKIQ  
SNAMA-A  GFLIPKNTTLIISRIPIAHPTKKGWEPPAAENAFSAAPAKQDNFNMDLSKMQGTEEDKIQ  
                 130       140       150       160       170       180      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  AMMMQSTVDYDPKTYHRIKGQSQVGEVPASYRCNKCKKSGHWIKNCPFVGGKDQQEVKRN   ZINC FINGER CCHC DOMAIN 
SNAMA-A  AMMMQSTVDYDPKTYHRIKGQSQVGEVPASYRCNKCKKSGHWIKNCPFVGGKDQQEVKRN  
                 190       200       210       220       230       240      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  TGIPRSFRDKPDAAENESADFVLPAVQNQEIPEDLICGICRDIFVDAVMIPCCGSSFCDD  
SNAMA-A  TGIPRSFRDKPDAAENESADFVLPAVQNQEIPEDLICGICRDIFVDAVMIPCCGSSFCDD   CYSTEIN RICH RING FINGER 
                 250       260       270       280       290       300      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  CVRTSLLESEDSECPDCKEKNCSPGSLIPNRFLRNSVNAFKNETGYNKSAAKPAAVKNEE  
SNAMA-A  CVRTSLLESEDSECPDCKEKNCSPGSLIPNRFLRNSVNAFKNETGYNKSAAKPAAVKNEE  
                 310       320       330       340       350       360      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  KPPVEKEVEKKPVAEVEPEETEVKPEKQKESETNGSNPPKSESPEPPATTEPSQKEKDKY   GLUTAMIC ACID RICH REGION 
SNAMA-A  KPPVEKEVEKKPVAEVEPEETEVKPEKQKESETNGSNPPKSESPEPPATTEPSQKEKDKY  
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                 370       380       390       400       410       420      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  DSDYEDNITIKMPQPAADSTTVPSKRSPSYSHRSESSHRRDRSDYVSDHDHKHQRPSKSE  
SNAMA-A  DSDYEDNITIKMPQPAADSTTVPSKRSPSYSHRSESSHRRDRSDYVSDHDHKHQRPSKSE 
                 430       440       450       460       470       480      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  SVNKDRSLLPLPIGTLPSYQGHMMAESEEARRSSAYKPPYMQMQRGPPPMHMMSHHMPAY        PROLINE RICH REGION  
SNAMA-A  SVNKDRSLLPLPIGTLPSYQGHMMAESEEARRSSAYKPPYMQMQRGPPPMHMMSHHMPAY 
                 490       500       510       520       530       540      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  NNGFNNMGQRPPLR----------------------------------------------  
SNAMA-A  NNGFNNMGQRPPLSYVPYQNQSVHPMRAPYGSAGGGMNMNMSQPFQSPNLASIYQGVAAK  
                 550       560       570       580       590       600      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  VGSGPIDDPLEAFNRIMKEKERKKVDRFRSSDRHRSRSPDRQRHRFKSPMYEKDNSRDNL        COILED COIL ? 
                 610       620       630       640       650       660      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  KDKRPRSRERKREHSYERHIRHPRSSRQPNDGSKSPGGRIKRSGHRRSASPKPGYKSDYR      
                 670       680       690       700       710       720      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  DKPYNKPSAPKTEAVEPPPPGFEPLQLTDEDGYRNKHPTSSEASQSSKGDSSKKRGENRH  
                 730       740       750       760       770       780      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  EEAPRKRHRSRSISKEPKPNDSNYRSLTPPAKITTPKMTAAQLRQRESSPKTPEKSHDDY        RB BINDING ? 
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                 790       800       810       820       830       840      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  LTAKARIMASQPVINDTEMETNVGKENKAKSPLSKDRKKKKKDKDKAERKKNKKDKRAKK                     
                 850       860       870       880       890       900      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A EKGDRQKKSSSVNRSDSDINNSSLMNESNYKVLSPRAQSPSIEINAAQLSPTHNATENVN  
 
                 910       920       930       940       950       960      
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  PKSHSILTVGAASDDNLGPRSKLSEANSVNLSKWEIDENILGLEDSSKKAAGASDDPSEI 
 
                 970       980       990       1000      1010      1020     
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  TSDVLRKAENAIFAKAINAIRPMEFQVIINSKDNSKDRSVVRSDKDRSSSPRRNNSSRSV  
 
                 1030      1040      1050      1060      1070      1080     
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  KDRLGTKISNDRSRSRDKSKGRRRAARSSDDDANRGRSDRHGSRKRDNRSRDRAAPSEKR  
                 1090      1100      1110      1120      1130      1140     
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------       
SNAMA-A  QERSYKRSSPEDDKLRRQNKEQSESKHGKHDQNNSDDSDRRAAKNTKSSDSRVVSSVTAV        p53 BINDING ?  
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Figure 21: Aligned protein sequences of SNAMA A and SNAMA B. The transcripts have identical sequences and the 
DWNN Catalytic module (DCM) functional domains are conserved in both transcripts. The possible locations of all functional 
domains are highlighted in grey with their labeling alongside the alignment. 
      
                 1150      1160      1170      1180      1190      1200     
         ....|....|....|....|....|....|....|....|....|....|....|....| 
SNAMA-B  ------------------------------------------------------------  
SNAMA-A  VAPPKPCRPDNPFRKFVDTSSSSSLVVKYDNTIQKEGASSDNGMEHRKQRDKKLKKHSKY  
                 1210      1220      1230  
         ....|....|....|....|....|....|. 
SNAMA-B  -------------------------------  
SNAMA-A  SSTDSLKSEKRKDPKSKKKSKILKKKKKSKK                                     LYSINE RICH REGION 
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Figure 22: A schematic overview of the possible domain structure 
of SNAMA isoforms. On comparison of the protein coding regions of 
the two isoforms we find that: SNAMA B shares the DCM (DWNN, Zinc 
Knuckle, RING finger), with SNAMA A. Furthermore, SNAMA B lacks 
downstream p53 and Rb binding domains as well as, coiled coil and 
lysine rich regions. 
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3.5 Differential expression of SNAMA during development 
and in response to DNA damage 
We have shown experimentally, the presence of the SNAMA B 
transcript by cDNA synthesis targeted at the gene, and amplification by 
subsequent PCR, shown in Figure 23 and 24. Specific primers were 
designed targeting the amplification of fragments of SNAMA A and B 
from wild type adult flies, Camptothecin treated adult flies as well as 
wild type fly embryos. Camptothecin causes DNA damage through the 
inhibition of DNA Topoisomerase 1. cDNA was synthesised using 
Oligo(dT) primers in one instance and SNAMA specific primers in 
another. cDNA synthesis using specific primers presents a limitation in 
that primers are not always able to bind the tail of the product cDNA 
making PCR amplification difficult.  
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Figure 23: SNAMA A was detected after Reverse Transcriptase 
PCR. cDNA synthesised using specific reverse primers from wildtype 
adult flies, camptothecin treated adult flies and 0-6hr fly embryos RNA, 
was used as a template for DNA amplification of SNAMA A and B using 
targeted primers. DNA was visualized on a 1% Agarose gel containing 
EtBr. Lanes 1, 3, 5 show SNAMA A from adults, camptothecin treated 
adults and embryos respectively, while lanes 2, 4 and 6 contain 
reactions targeted at amplifying SNAMA B. SNAMA A is present in all 
three instances, whereas SNAMA B is present after DNA damage. 
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Figure 24: SNAMA B was detected after Reverse Transcriptase 
PCR. Using RNA from wildtype adult flies, camptothecin treated adult 
flies and 0-6hr fly embryo’s cDNA synthesis was performed with 
Oligo(dT) primers. DNA was amplified by PCR using specific forward 
and reverse primers. DNA was visualized on a 1% Agarose gel 
containing EtBr. Lanes 4 and 6 shows SNAMA B from camptothecin 
treated adults and untreated embryo’s respectively. Lanes 1, 3 and 5 
contain reactions targeted at amplifying SNAMA A. Lane 2 shows that 
SNAMA B was not amplified from wild type adult flies, but was present 
after DNA damage and during embryonic development. 
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4. Discussion 
This study has revealed more information on expression patterns as 
well as the existence of two isoforms of SNAMA (a possible interacting 
partner of Dmp53). SNAMA gene studies have revealed two alternative 
splice sites for SNAMA. Furthermore, PCR studies have shown, 
experimentally, the existence of the transcripts that are formed by 
alternative splicing. The SNAMA B transcript is stimulated by DNA 
damage and also appears in developing fly embryos.  
The study aimed at identifying interacting partners for Drosophila p53, 
using heterologous expression of proteins and chromatography, 
followed by immunoprecipitation studies to identify interacting 
proteins. Small amounts of soluble Dmp53 were expressed in yeast 
expression experiments and the protein was found only in inclusion 
bodies in prokaryotic systems. Refolding these proteins proved 
insurmountable leading to the employment of the eukaryotic system. 
The unavailability of high quality commercial antibodies prevented 
protein interactions studies. Consequently, interaction studies were not 
concluded in this study. In this section, the key discoveries about the 
expression of the SNAMA gene and its possible involvement in 
genotoxic stress are discussed. Furthermore, insights are made about 
the implications of these transcription developments with regard to the 
interaction of SNAMA with other proteins. 
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4.1 SNAMA B, a shorter SNAMA isoform comprises an 
independent DWNN Catalytic module and is activated by DNA 
damage. 
A recent review of the flybase Drosophila genome has shown the 
possible existence of a second SNAMA isoform. We have studied the 
sequences of the proposed transcripts and have concluded that SNAMA 
is alternatively spliced to produce two transcripts. The 1231 amino 
acid SNAMA isoform yielding a predicted protein of 139 kDa is encoded 
from a 3.9 kb transcript. SNAMA B has a 494 amino acid isoform, giving 
rise to a predicted 55 kDa protein and encoded by a 2.1 kb transcript. 
The transcripts differ in their 5ˊ untranslated regions, with SNAMA A 
(the longer transcript) having a shorter UTR. Both transcripts encode 
the DCM, consisting the DWNN, Zink knuckle and Cysteine Ring finger 
as well as glutamic acid and proline rich regions. These transcripts 
should therefore share identical functions and be involved in the same 
processes and pathways related to the DCM. The presence of a proline 
rich region in both isoforms also indicates possible nucleic acid 
interactions and interactions with other proteins. Proline rich regions 
have been shown to bind a variety of motifs (Kay et al., 2000). 
Alternative splicing introduces a stop codon in exon 5, producing 
transcript B. The majority of SNAMA B is thus made up of the DWNN 
Catalytic Module. This suggests that SNAMA B functions and exists in a 
similar fashion to the mammalian  independent DWNN isoform of 
RBBP6, which also lacks downstream binding domains and has been 
suggested  to play a role in regulation of the cell cycle, and to  be down 
regulated in cancers (Mbita et al., 2011).  
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Possible downstream functional domains which only occur in the full 
length SNAMA A transcript include the RB and p53 binding domains 
and coiled-coil and lysine rich regions. We expect that SNAMA A may 
interact with other proteins and perhaps with nucleic acids due to the 
presence of these domains. According to Ntwasa (2008), the presence 
of the coiled-coil domain further suggests interactions with other 
proteins and possible dimerization of the isoform. Proteins with coiled-
coil domains are often implicated in the control of oligomerization and 
interact with various structures including the Golgi apparatus, 
cytoskeleton, nuclear matrix centromere and centrosomes and 
chromatin (Ntwasa, 2008). Furthermore, both SNAMA A and B may 
have other interactions with Dmp53 owing to the presence of the DCM. 
These are most probable through E3 ligase activity in apoptosis and 
ubiquitin pathways. Hull and Ntwasa (2010), also suggest that SNAMA 
isoforms may be integral in DNA damage response. Interestingly Hull 
(2012), has shown a 55kDa protein detected through Western analyses 
with anti-SNAMA antibodies after methyl pyruvate treatment but not 
after Camptothecin treatment. It is possible that this protein is SNAMA 
B and was amplified here through PCR after treatment with either 
camptothecin or methyl pyruvate. Since PCR is a more sensitive 
detection method, the Western analysis may have failed to detect small 
amounts of protein. This suggests that SNAMA B is present as a 
transcript after DNA damage but may not be expressed in high levels 
after only camptothecin treatment and that expression may be 
enhanced by methyl pyruvate treatment. 
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4.2 SNAMA A and B are probably differentially expressed 
during embryonic development and induced by DNA damage  
SNAMA is crucial for embryonic development, having a probable role in 
suppressing apoptosis(Hull and Ntwasa, 2010). Furthermore, knockout 
studies have shown that a lack of SNAMA is lethal (Mather et al., 2005). 
Similarly Dmp53 is expressed throughout development (Jin et al., 
2000) and programmed cell death is known to have an important role 
during development (Bangs and White, 2000). Studies into the effect of 
camptothecin induced apoptosis on human RBBP6 has shown an 
upregulation of RBBP6 promoters (Pretorius et al., 2011). During early 
embryonic development, SNAMA expression is considerably higher. 
SNAMA A is present in early stages of embryonic development and 
expression is reduced in late stages.  
 
The study was also able to show the existence of the SNAMA B 
transcript experimentally. SNAMA B did not seem to be present in 
normal adult flies but was amplified from cDNA with poly A tails using 
specific primers in wild type 0-6 hour embryos, as well as adults with 
camptothecin induced DNA damage. PCR using cDNA amplified from 
specific primers as a template was successful in amplifying SNAMA A in 
adult flies; camptothecin treated adult flies, as well as 0-6 hour fly 
embryos. SNAMA B using this specifically amplified cDNA, was present 
in adult flies that had undergone camptothecin treatment. This 
suggests that SNAMA B is upregulated after DNA damage. 
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This further suggests that SNAMA, like its counterparts (RBBP6), is 
involved in apoptosis and interacts with Dmp53. Upon DNA damage, 
p53 triggers apoptosis through the ubiquitin proteasome system  in 
which it is suspected that SNAMA is an active ubiquitin like modifier, 
due to the presence of a DCM (Cajee et al., 2012).  
 
4.3 Dmp53 interactors 
In order to study Dmp53 interactions with other proteins, a 
recombinant Dmp53 needed to be expressed, and purified. This protein 
would then be used in immune precipitation studies. Initial expression 
of Dmp53 was carried out using a bacterial expression system (E. coli, 
transformed with Dmp53 DNA in pET41a plasmid), Human p53 is 
routinely cloned expressed in a similar way as described by Midgley et 
al., (1992). It was found that Dmp53 in the bacterial expression system 
was expressed as insoluble inclusion bodies regardless of time period 
of induction. The protein can sometimes be solubilised and refolded, 
however, methods are still cumbersome and expensive and often result 
in poor recovery of protein (Singh and Panda, 2005). Also, these 
techniques may render the protein unusable in further studies, if 
antibody epitopes are disrupted. By changing the expression system, 
the study then attempted to express already soluble protein. 
 
A yeast expression system was used in order to express soluble 
Dmp53, after bacterial expression had expressed the protein as 
insoluble inclusion bodies. Yeast expression systems offer a step up 
from prokaryotic/bacterial expression systems, for example post 
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translational modifications and secretory expression. Yeast grow on 
simple media to high cell densities, and have advanced genetics 
amongst eukaryotes, allowing easy manipulation similar to 
manipulation of E. coli (Romanos et al., 1992). The eukaryotic yeast  
subcellular organisation  can carry out the necessary post translational 
modifications (including disulphide bonds, glycosylation, proteolytic 
modification and other modifications)  needed for complex proteins, 
through its multi-component apparatus (Madzak et al., 2004).  
 
Yeast was transformed with a Dmp53 DNA fused with a HIS tag in 
pTG1895. The pTG1895 plasmid used in yeast protein expression, 
included the factor alpha pre-pro cassette in its sequence. Upon 
expression, the cassette signals the secretion of the protein by the cell, 
to the culture media, making extraction and purification of expressed 
protein simpler. Upon experimentation we were not able to retrieve 
Dmp53 from the secreted into the supernatant but were able to detect 
and purify soluble Dmp53 protein expressed and retained in the 
cytosol. The difficulties in expressing secreted protein could be due to 
the choice of Yeast strain, where S. cerevisiae is becoming less popular 
having found to be limiting in many factors for example, low product 
yield, low secretion capacity as well as poor plasmid stability amongst 
others (Madzak et al., 2004). Another limiting factor may also be that 
yeast cells exhibit a high codon bias (Akashi, 2003). 
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We were able to express soluble Dmp53 protein in yeast; however, the 
level of expression was low. Proteins from crude extracts were not 
visible on stained SDS PAGE gels. Concentrating the extracts by TCA 
precipitation or stirred cell filtration proved effective in making 
proteins visible. Later the quantity of expression increased slightly 
with the inclusion of protease inhibitors, however, protein yield from 
large cultures, was not enough for further biological studies. The use of  
a yeast strain with impaired proteolytic function could further enhance 
peptide recovery (Thill et al., 1986) .  
 
The study demonstrated the heterologous expression of a suspected 
soluble Dmp53 protein in yeast. The protein size after electrophoresis 
matched the expected size from calculations. Thus, the protein was 
purified out of crude extract through HIS nickel select chromatography. 
However, a benchmark for positive identification of a protein is 
immunoblotting. Unfortunately, due to non-specific antigen antibody 
binding it could not be confirmed that the expressed protein was 
Dmp53. The study had used/tested three different anti-Dmp53 
antibodies, having different epitopes. It was found that these antibodies 
bind non-specifically. Furthermore, there was great variation in the 
antibody properties per batch. All these were polyclonal antibodies, as 
monoclonal Dmp53 antibodies were not readily available. 
 
Immunoprecipitation studies use specific antibody antigen interactions 
to pull down a protein of interest together with possible interacting 
partners. The availability of an A grade specific Dmp53 antibody is thus 
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essential to further study Dmp53. We were unable to perform 
immunoprecipitation studies, as all readily available commercial 
antibodies bind non-specifically (as shown in Western blot analyses), 
and thus could not reliably be used. 
 
Protein interactions, between Dmp53 and SNAMA, can only be 
confirmed with further research after Dmp53, as well as SNAMA, can 
be efficiently expressed and purified in their soluble states. In addition, 
specific monoclonal antibodies directed towards both Dmp53 and 
SNAMA, must be developed to ensure accurate results. We can thus 
only speculate that SNAMA interacts with Dmp53 in one or more 
systems, where both proteins are present, involved or upregulated. 
Likely interations may occur in the ubiquitin system due to the DCM of 
SNAMA and Dmp53’s role in apoptosis, after DNA damage, and during 
fly embryonic development. 
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5.  Conclusion 
i. SNAMA is alternatively spliced to produce two isoforms. 
ii. The expression of alternate splice forms of SNAMA is dependent 
on DNA damage and developmental stages. 
iii. SNAMA domain structure and its upregulation after DNA damage 
suggests possible interactions with Dmp53, and/or the Ubiquitin 
system and other proteins. 
iv. Overexpression of truncated Dmp53 in a bacterial 
overexpression system resulted in an insoluble protein that 
could not be purified or refolded. 
v. The yeast expression system resulted in native full length 
Dmp53 but it was only expressed in small amounts. 
 
5.1 Future work 
i. Effective overexpression of native Dmp53 will require the 
development of an alternative overexpression system. Ideally, 
this would be yeast based and the vector used will be effective in 
attaching an export signal to the Dmp53 protein resulting in its 
export from the cell. 
ii. In order for this research to proceed, an antibody, which binds 
Dmp53 specifically, would need to be developed.  
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Appendix A, Dmp53 in pET41a sequence 
Sequence of Dmp53 insert in pET41a with primer locations and 
restriction site 
1     TTAACTTTAA GAAGGAGATA TACATATGTC CCCTATACTA GGTTATTGGA AAATTAAGGG 
      AATTGAAATT CTTCCTCTAT ATGTATACAG GGGATATGAT CCAATAACCT TTTAATTCCC 
 
61    CCTTGTGCAA CCCACTCGAC TTCTTTTGGA ATATCTTGAA GAAAAATATG AAGAGCATTT 
      GGAACACGTT GGGTGAGCTG AAGAAAACCT TATAGAACTT CTTTTTATAC TTCTCGTAAA 
 
121   GTATGAGCGC GATGAAGGTG ATAAATGGCG AAACAAAAAG TTTGAATTGG GTTTGGAGTT 
      CATACTCGCG CTACTTCCAC TATTTACCGC TTTGTTTTTC AAACTTAACC CAAACCTCAA 
 
181   TCCCAATCTT CCTTATTATA TTGATGGTGA TGTTAAATTA ACACAGTCTA TGGCCATCAT 
      AGGGTTAGAA GGAATAATAT AACTACCACT ACAATTTAAT TGTGTCAGAT ACCGGTAGTA 
 
241   ACGTTATATA GCTGACAAGC ACAACATGTT GGGTGGTTGT CCAAAAGAGC GTGCAGAGAT 
      TGCAATATAT CGACTGTTCG TGTTGTACAA CCCACCAACA GGTTTTCTCG CACGTCTCTA 
 
301   TTCAATGCTT GAAGGAGCGG TTTTGGATAT TAGATACGGT GTTTCGAGAA TTGCATATAG 
      AAGTTACGAA CTTCCTCGCC AAAACCTATA ATCTATGCCA CAAAGCTCTT AACGTATATC 
 
361   TAAAGACTTT GAAACTCTCA AAGTTGATTT TCTTAGCAAG CTACCTGAAA TGCTGAAAAT 
      ATTTCTGAAA CTTTGAGAGT TTCAACTAAA AGAATCGTTC GATGGACTTT ACGACTTTTA 
 
421   GTTCGAAGAT CGTTTATGTC ATAAAACATA TTTAAATGGT GATCATGTAA CCCATCCTGA 
      CAAGCTTCTA GCAAATACAG TATTTTGTAT AAATTTACCA CTAGTACATT GGGTAGGACT 
 
481   CTTCATGTTG TATGACGCTC TTGATGTTGT TTTATACATG GACCCAATGT GCCTGGATGC 
      GAAGTACAAC ATACTGCGAG AACTACAACA AAATATGTAC CTGGGTTACA CGGACCTACG 
 
541   GTTCCCAAAA TTAGTTTGTT TTAAAAAACG TATTGAAGCT ATCCCACAAA TTGATAAGTA 
      CAAGGGTTTT AATCAAACAA AATTTTTTGC ATAACTTCGA TAGGGTGTTT AACTATTCAT 
 
601   CTTGAAATCC AGCAAGTATA TAGCATGGCC TTTGCAGGGC TGGCAAGCCA CGTTTGGTGG 
      GAACTTTAGG TCGTTCATAT ATCGTACCGG AAACGTCCCG ACCGTTCGGT GCAAACCACC 
 
   Forward primer with HindIII cut site 5’TAGTGAA GCTTGTCATC ACCAT 3’ 
661   TGGCGACCAT CCTCCAAAAT CGGATGGTTC AACTAGTGGT TCTGGTCATC ACCATCACCA 
      ACCGCTGGTA GGAGGTTTTA GCCTACCAAG TTGATCACCA AGACCAGTAG TGGTAGTGGT 
 
721   TCACTCCGCG GGTCTGGTGC CACGCGGTAG TACTGCAATT GGTATGAAAG AAACCGCTGC 
      AGTGAGGCGC CCAGACCACG GTGCGCCATC ATGACGTTAA CCATACTTTC TTTGGCGACG 
 
781   TGCTAAATTC GAACGCCAGC ACATGGACAG CCCAGATCTG GGTACCGGTG GTGGCTCCGG 
      ACGATTTAAG CTTGCGGTCG TGTACCTGTC GGGTCTAGAC CCATGGCCAC CACCGAGGCC 
                       
841   TGATGACGAC GACAAGAGTC CCATGGGATA TCGGGGATCC ATGTACTCGA TTCCGCTGAA 
      ACTACTGCTG CTGTTCTCAG GGTACCCTAT AGCCCCTAGG TACATGAGCT AARGCGACTT 
 
901   CAAGCTCTAC ATCCGGATGA ACAAGGCCTT CAACGTGGAC GTTCAGTTTA AGTCTAAGAT 
      GTTCGAGATG TAGGCCTACT TGTTCCGGAA GTTGCACCTG CAAGTCAAAT TCAGATTCTA 
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961   GCCCATCCAG CCACTTAATT TGCGTGTGTT CCTTTGCTTC TCCAATGATG TCAGTGCTCC 
      CGGGTAGGTC GGTGAATTAA ACGCACACAA GGAAACGAAG AGGTTACTAC AGTCACGAGG 
 
1021  CGTGGTCCGC TGTCAAAATC ACCTTAGCGT TGAGCCTTTG ACGGCCAATA ACGCAAAAAT 
      GCACCAGGCG ACAGTTTTAG TGGAATCGCA ACTCGGAAAC TGCCGGTTAT TGCGTTTTTA 
 
1081  GCGCGAGAGC TTGCTGCGCA GCGAGAATCC CAACAGTGTA TATTGTGGAA ATGCTCAGGG 
      CGCGCTCTCG AACGACGCGT CGCTCTTAGG GTTGTCACAT ATAACACCTT TACGAGTCCC 
 
1141  CAAAGGAATT TCCGAGCGTT TTTCCGTTGT AGTCCCCCTG AACATGAGTC GGTCTGTAAC 
      GTTTCCTTAA AGGCTCGCAA AAAGGCAACA TCAGGGGGAC TTGTACTCAG CCAGACATTG 
 
1201  CCGCAGTGGG CTCACGCGCC AGACCCTGGC CTTCAAGTTC GTCTGCCAAA ACTCGTGTAT 
      GGCGTCACCC GAGTGCGCGG TCTGGGACCG GAAGTTCAAG CAGACGGTTT TGAGCACATA 
 
1261  CGGGCGAAAA GAAACTTCCT TAGTCTTCTG CCTGGAGAAA GCATGCGGCG ATATCGTGGG 
      GCCCGCTTTT CTTTGAAGGA ATCAGAAGAC GGACCTCTTT CGTACGCCGC TATAGCACCC 
 
1321  ACAGCATGTT ATACATGTTA AAATATGTAC GTGCCCCAAG CGGGATCGCA TCCAAGACGA 
      TGTCGTACAA TATGTACAAT TTTATACATG CACGGGGTTC GCCCTAGCGT AGGTTCTGCT 
 
1381  ACGCCAGCTC AATAGCAAGA AGCGCAAGTC CGTGCCGGAA GCCGCCGAAG AAGATGAGCC 
      TGCGGTCGAG TTATCGTTCT TCGCGTTCAG GCACGGCCTT CGGCGGCTTC TTCTACTCGG 
 
1441  GTCCAAGGTG CGTCGGTGCA TTGCTATAAA GACGGAGGAC ACGGAGAGCA ATGATAGCCG 
      CAGGTTCCAC GCAGCCACGT AACGATATTT CTGCCTCCTG TGCCTCTCGT TACTATCGGC 
 
1501  AGACTGCGAC GACTCCGCCG CAGAGTGGAA CGTGTCGCGG ACACCGGATG GCGATTACCG 
      TCTGACGCTG CTGAGGCGGC GTCTCACCTT GCACAGCGCC TGTGGCCTAC CGCTAATGGC 
 
1561  TCTGGCTATT ACGTGCCCCA ATAAGGAATG GCTGCTGCAG AGCATCGAGG GCATGATTAA 
      AGACCGATAA TGCACGGGGT TATTCCTTAC CGACGACGTC TCGTAGCTCC CGTACTAATT 
 
1621  AGGAGGCGGC GGCTGAAGTC CTGCGCAATC CCAACCAAGA GAATCTACGT CGCCATGCCA 
      TCCTCCGCCG CCGACTTCAG GACGCGTTAG GGTTGGTTCT CTTAGATGCA GCGGTACGGT 
 
1681  ACAATTGCTG AGCCTTAAGA AACGTGCCTA CGAGCTGCCA TGAAAGCTTG CGGCCGCACT 
      TGTTAACGAC TCGGAATTCT TTGCACGGAT GCTCGACGGT ACTTTCGAAC GCCGGCGTGA 
       Forward primer with SalI cut site   3’ GGT ACTTCAGCTG GCCG 5’                           
 
1741  CGAGCACCAC CACCACCACC ACCACCACTA ATTGATTAAT ACCTAGGCTG CTAAACAAAG 
      GCTCGTGGTG GTGGTGGTGG TGGTGGTGAT TAACTAATTA TGGATCCGAC GATTTGTTTC 
 
1801  CCCGAAAGGA AGCTGAGTTG GCTGCTGCCA CCGCTGAGCA ATAACTAGCA TAACCCCTTG 
      GGGCTTTCCT TCGACTCAAC CGACGACGGT GGCGACTCGT TATTGATCGT ATTGGGGAAC 
 
1861  GGGCCTCTAA ACGGGTCTTG AGGGGTTTTT TGCTGAAAGG AGGAACTATA TCCGGAT 
      CCCGGAGATT TGCCCAGAAC TCCCCAAAAA ACGACTTTCC TCCTTGATAT AGGCCTA 
 
Key: Primer Sequences, Pet41a Sequence, Dmp53 insert, Pet41a HIS tag 
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Appendix B, pGEM-T Easy  
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Appendix C, pET41a 
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Appendix D, pTG1895 
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Appendix E, Generuler 1kb plus 
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Appendix F, PageRuler Protein ladder 
 
 
